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Abstract 
Feline sarcoma-related (FER) kinase is a ubiquitous non-receptor tyrosine kinase 
overexpressed in many cancer types. It promotes proliferation, migration and metastasis in 
prostate, lung and ovarian carcinoma cells, respectively. However, the biological roles of FER 
in human metastatic melanoma have not been explored. I used a doxycycline-inducible, 
lentivirus-based shRNA approach to silence FER kinase expression in the 131/4-5B1 human 
melanoma (hereafter termed 5B1) cells. I determined fewer FER-deficient 5B1 cells in the S-
phase of the cell cycle and reduced motility of FER-deficient 5B1 cells, suggesting that FER 
promotes 5B1 cell cycle transit and migration. In vivo chorioallantoic membrane (CAM) 
studies demonstrate that FER-deficient 5B1 cells have an increased capacity to invade into 
CAM mesoderm and that both FER-expressing and FER-deficient tumours acquire endothelial 
cells within the tumour. My study outlines a novel role for FER kinase in 5B1 cell proliferation, 
migration and invasion.  
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Chapter 1  
1 Introduction 
1.1 Melanocytes as the cells of origin of melanoma 
Melanomas are some of the most aggressive human tumours and arise mainly from 
carcinogenic transformation of epidermal melanocytes. In Canada, the incidence of 
melanoma has been steadily rising over the past several decades. Of all cancers, melanoma 
has the 7th highest incidence rate in Canada and about 1.2-1.9 % of cancer deaths in Canada 
will be due to melanoma (Canadian Cancer Society, 2017).  
Melanocytes are melanin-producing cells that originate from the embryonic neural crest. 
After birth, melanocytes are found in the basal layer of the epidermis (Figure 1.1), in hair 
follicles, cochlea, iris, meninges and in the heart (Cichorek et al., 2013). A subset of cells 
that migrates from the neural crest, differentiates into melanoblasts, which are cell 
precursors that later become melanocyte stem cells and terminally-differentiated 
melanocytes (Yamaguchi and Hearing, 2014). Melanocytes provide tissue pigmentation by 
producing melanin within lysosome-like organelles termed melanosomes (Lin and Fisher, 
2007). In the skin, melanosomes are transferred from melanocytes to adjacent 
keratinocytes. The melanin-containing granules are trafficked to perinuclear regions in 
keratinocytes, forming a protective cap that shields genomic DNA from the harmful effects 
of solar ultraviolet (UV) radiation (Hearing, 2005). The photoprotective characteristics of 
melanin include its ability to absorb UV radiation and scavenge reactive oxygen species 
(ROS) (Brenner and Hearing, 2008). Physiologically, keratinocyte exposure to UV  
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Figure 1.1. Schematic of the epidermis 
The epidermis is composed of 5 cell layers. The innermost layer, stratum basale, contains 
the melanocytes that produce melanin and transfer them in melanosomes to adjacent 
keratinocytes. The melanin-containing granules (brown dots) form a protective cap over 
keratinocyte nuclei to shield genomic DNA from solar UV radiation. 
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radiation results in increased transcription of the pro-opiomelanocortin (POMC) gene, 
which is required for the production and secretion of melanocyte stimulating hormone (α-
MSH). α-MSH released from keratinocytes binds to and activates melanocortin 1 receptors 
(MC1R) on melanocytes, resulting in intracellular cAMP production followed by protein 
kinase A (PKA) activation. PKA then activates other proteins and transcription factors, 
such as the microphthalmia-associated transcription factor (MITF), that are involved in the 
transcription of enzymes necessary for melanin biosynthesis (D’Orazio et al., 2013).  
Excessive exposure to UV radiation is the leading contributor to malignant transformation 
of melanocytes. Solar UV radiation can be categorized into three types: UVA, UVB and 
UVC.  UVC (100-280 nm) is predominantly absorbed by the atmospheric ozone layer, thus 
humans are normally not exposed to it. UVA (315-400 nm) can penetrate deep into the 
dermis of the skin, whereas UVB (280-315) is absorbed predominantly by the epidermis 
(D’Orazio et al., 2013). UV radiation can lead to direct DNA damage, through the 
formation of cyclobutene pyrimidine dimers. Additionally, UVA exposure can result in 
production of ROS, which can cause single or double DNA strand breaks. These DNA 
lesions can subsequently lead to genetic mutations and tumour formation (Jhappan et al., 
2003).  
Melanocytes can synthesize two types of melanin, pheomelanin and eumelanin. Eumelanin 
is a brown/black pigment, whereas pheomelanin is a red/yellow pigment. Both types of 
melanin are synthesized by the same types of enzymes (Lin and Fisher, 2007). The amount 
of eumelanin present in the skin determines its colour, and increased eumelanin levels are 
responsible for darker skin tones (D’Orazio et al., 2013). Pheomelanin is typically found 
among red-haired individuals (Brenner and Hearing, 2008). The photoprotective properties 
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of eumelanin are superior to those of pheomelanin. Consequently, light-skinned and red-
haired individuals are at a higher risk of developing melanoma (Roider and Fisher, 2016).  
Although exposure to UV radiation is the main cause of melanoma, there are subsets of 
human populations, which develop melanomas not associated with UV exposure. 
Examples are acral lentiginous melanoma and mucosal melanoma, which have been found 
in large numbers of individuals in Asian, African and some Latin American countries and 
develop in body areas not generally exposed to solar UV radiation (Ossio et al., 2017). The 
recent discovery of germline mutations that influence predisposition to melanoma, suggest 
that future research should also focus on individuals of non-European descent (Ossio et al., 
2017).  
1.2 Driver genetic mutations in melanoma   
Mutations that directly confer a selective growth or survival advantage to transformed cells 
are termed driver mutations. In the context of melanoma, a single driver mutation is not 
sufficient for melanoma formation. Mutations in tumour cell genomes that do not influence 
cancer development, are termed passenger mutations (Stratton et al., 2009). Several 
melanoma driver gene mutations have been identified. The most common somatic 
mutation, which accounts for about 60% of all human melanomas, is in the BRAF gene, 
which encodes the serine/threonine protein kinase B-RAF (Ascierto et al., 2012). The latter 
functions in the mitogen-activated protein kinase (MAPK) pathway. Over 90% of B-RAF 
mutations result from a single nucleotide alteration that replaces valine at position 600 for 
glutamic acid (B-RAFV600E), leading to constitutive activation of B-RAF (Ascierto et al., 
2012). The MAPK pathway can be activated by several events. These events include ligand 
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binding to receptor tyrosine kinases (RTK), such as epidermal growth factor receptor 
(EGFR), c-KIT and platelet-derived growth factor receptor (PDGFR), with the subsequent 
activation of RAS, a small GTPase that localizes to the plasma membrane. RAS, in its 
active GTP-bound form, causes phosphorylation of RAF. RAF phosphorylates MEK, and 
then MEK phosphorylates and activates ERK, resulting in the activation of several 
responses, including the transcription of genes involved in cell proliferation and survival 
(Fecher et al., 2008) (Figure 1.2).  
The second most common melanoma driver mutation, observed in about 20 % of tumours, 
is in the NRAS gene. Mutations that replace glutamine at position 61 with lysine or arginine 
are more prevalently seen, resulting in the synthesis of a constitutively active N-RAS 
protein (Johnson and Puzanov, 2015). N-RAS belongs to the family of RAS GTPases, and 
functions as a key component in the MAPK and phosphoinositide 3-kinase (PI3K) 
signalling pathways (Mehnert and Kluger, 2012). PI3K is activated in response to ligand 
binding to RTKs, G protein-coupled receptors (GPCRs) or RAS activation through GTP 
binding, hence mutant N-RAS leads to constitutive activation of PI3K. Active PI3K is 
responsible for the conversion of phosphatidylinositol-(3,4)-P2 (PIP2) to 
phosphatidylinositol-(3,4,5)-P3 (PIP3). PIP3 interacts with numerous proteins including 
AKT which is a serine/threonine kinase that becomes activated upon phosphorylation, and 
then activates other downstream effectors, such as mTOR, which is involved in regulating 
cell survival and growth. The overall activity of the PI3K pathway is negatively regulated 
by the phosphatase PTEN, and, significantly, mutations in PTEN are also observed in 
melanoma (Davies, 2012; Mehnert and Kluger, 2012) (Figure 1.3).  
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Figure 1.2. MAPK signaling pathway 
Receptor tyrosine kinases (RTKs) are activated by ligand binding. Grb2 binds to the 
activated receptor and to Sos, forming the Grb2/Sos complex. Sos then promotes the 
activation of RAS by removing GDP. The GTP-bound active RAS causes phosphorylation 
of RAF. RAF then phosphorylates MEK and MEK phosphorylates ERK. Active ERK 
promotes the transcription of genes involved in cellular proliferation and survival.  
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Figure 1.3. PI3K signaling pathway 
PI3K is comprised of a regulatory and catalytic subunit termed p85 and p110, respectively.  
PI3K is activated by ligand-bound receptor tyrosine kinases (RTKs), G protein-coupled 
receptors (GPCR) or GTP-bound RAS. Active PI3K interacts with lipid substrates on the 
plasma membrane and results in the formation of PIP3 from PIP2.  PIP3 phosphorylates and 
activates AKT and AKT then activates downstream effectors involved in the regulation of 
cell survival and growth. PTEN negatively regulates the PI3K pathway by reversing the 
PIP2 to PIP3 conversion.  
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Mutations in RAC1 are found in 9% of cutaneous melanomas (Krauthammer et al., 2012). 
RAC1 belongs to a family of small GTPases, that modulate cell proliferation, migration 
and cytoskeletal organization (Krauthammer et al., 2012). The driver RAC1 mutation is a 
substitution of proline for serine at position 29, which favours the active GTP-bound state 
of RAC1 (Hodis et al., 2012).  
NF1 (neurofibromin 1) mutations are present in 14% of melanomas (Manzano et al., 2016) 
NF1 is a RAS GTPase-activating protein (GAP), and mutations in this protein lead to 
sustained activation of RAS and the MAPK and PI3K pathways (Nissan et al., 2014).  
1.3 Other common genetic mutations found in melanoma   
Other somatic mutations that contribute to melanoma formation and progression include 
those in the TERT and Kit genes (Reddy et al., 2017; Mehnert and Kluger, 2012). TERT 
encodes the catalytic subunit of telomerase, a protein that functions in the maintenance of 
telomere length in chromosomes. The expression of TERT in adult human somatic cells is 
repressed. However, in many human cancers, including melanoma, TERT expression is 
reactivated allowing cells to maintain telomere length and bypass senescence (Horn et al., 
2013). KIT encodes a transmembrane RTK, and mutations in this gene lead to expression 
of a constitutively active receptor and subsequent activation of the MAPK and PI3K 
pathways (Curtin et al., 2006).  
Germline mutations that increase susceptibility to melanoma have also been identified. 
Mutations in the CDKN2A gene have been found in 30% - 40% of families that are highly 
susceptible to melanoma. CDKN2A encodes two proteins involved in the regulation of cell 
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proliferation: p16INK4A and p14ARF. p16INK4A is involved in inducing cell cycle arrest in the 
G1 phase of the cell cycle by inhibiting phosphorylation of the retinoblastoma protein (RB) 
by cyclin-dependent kinase 4 (CDK4). p14ARF also induces cell cycle arrest and apoptosis 
through mechanisms that involve p53 (Reddy et al., 2017).  
The second most common melanoma germline mutation occurs in the CDK4 gene, which 
encodes CDK4, a protein involved in the transition from G1 to the S-phase of the cell cycle. 
The resulting CDK4 mutant protein is not inhibited by p16INK4A, resulting in abnormal cell 
cycle progression (Potrony et al., 2015).   
1.4 Melanoma progression and clinical staging   
Cutaneous melanoma can arise from chronically sun-damaged (CSD) and non-CSD skin. 
Melanomas from CSD skin develop on areas of the body with increased exposure to solar 
UV radiation, such as the head and neck, and frequently have mutations in N-RAS, KIT and 
B-RAF. Disease onset for this type of melanoma generally occurs in individuals over 50 
years of age. Melanomas from non-CSD skin are found in areas of the body with 
intermittent UV exposure, such as the torso, arms and legs, and generally exhibit fewer 
genetic mutations. Melanomas from non-CSD skin predominantly acquire the B-RAFV600E 
mutation, and disease onset generally occurs earlier in life (Eggermont et al., 2014; Shain 
and Bastian, 2016).  
Melanoma progression occurs in five stages termed acquired naevus, intermediate 
neoplasm (or dysplastic naevus), melanoma in situ, invasive melanoma and metastatic 
melanoma. The first stage, acquired naevus, forms as a consequence of benign 
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hyperproliferation of melanocytes, and is directly responsible for the formation of 20 to 
50% of melanomas (Damsky and Bosenberg, 2017). Melanocytic nevi frequently have B-
RAFV600E mutations, and are commonly associated with the formation of melanomas in 
non-CSD skin (Kumar et al., 2004; Roh et al., 2015). Abnormal B-RAF or N-RAS activity 
leading to constitutive MAPK signalling is observed in acquired naevi (Tan et al., 2017).  
Although most naevus cells become senescent, a few can acquire additional mutations and 
retain their ability to proliferate. The accumulation of additional genetic alterations 
promotes naevus transformation towards malignancy, including the loss of p16INK4A and 
activation of the PI3K pathway (Roh et al., 2015). Dysplastic naevus is considered a pre-
malignant lesion. The distinction between an acquired naevus and dysplastic naevus has 
often been an area of discussion; however, dysplastic nevi are lesions that have acquired 
multiple driver mutations in addition to B-RAF (Shain and Bastian, 2016). 
The third stage in melanoma progression, melanoma in situ, refers to the proliferation of 
melanoma cells within the epidermis, forming irregularly shaped lesions that can be 
precursors to invasive melanomas. These lesions are more commonly found in areas of the 
body chronically exposed to the sun.  Additional mutations in genes encoding B-RAF, N-
RAS and/or NF1, result in increased activity of the MAPK signalling pathways in these 
cells. Increased frequency of TERT mutations has also been observed in these cells. In situ 
melanomas can become invasive with the acquisition of additional mutations, including 
those that activate the MAPK pathway, as well as mutations in CDKN2A. Melanoma cells 
that move towards surrounding mesenchymal tissues such as the dermis or submucosa, 
enter stage four and are termed invasive melanoma (Shain and Bastian, 2016).  
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The last stage in melanoma progression is metastasis, which involves the migration of 
melanoma cells from the primary tumour to other organs in the body. Unlike the previously 
described stages, cells in metastatic melanoma are not distinctly characterized by a given 
subset of mutations, which contributes to their heterogeneity, unpredictable nature and 
resistance to treatment (Shain et al., 2015). It is therefore not surprising that prognosis is 
poor upon diagnosis of metastasis. Patients with metastatic melanoma have an expected 5-
year survival rate of only 5-20% (Long et al., 2012; Sandru et al., 2014). For this reason, 
intense efforts to develop therapies for metastatic melanoma continue at present.  
Clinically, melanoma is categorized into one of four stages, with Stage 0 describing 
melanoma in situ. Each stage is further divided to identify differences in primary melanoma 
tumour thickness, number of affected lymph nodes and distant metastases. Stages I and II 
encompass localized melanoma, stage III categorizes regional metastatic melanomas and 
stage IV is used when distant metastases are present (Balch et al., 2009).  
Patient survival is partly influenced by the location of melanoma dissemination. For 
example, regional metastasis within the skin, or to lymph nodes are associated with a higher 
overall survival in individuals. Patient survival progressively declines with melanoma 
metastases to the lungs and to the central nervous system (Sandru et al., 2014). Numerous 
studies have reported that individuals with brain metastasis have the poorest overall 
survival (Staudt et al., 2010; Flanigan et al., 2011; Davies et al., 2011). These observations 
outline the importance of early, accurate detection and staging of melanoma.  
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1.5 Current therapies for melanoma  
Surgery is the first line of treatment for cutaneous melanoma in those cases in which the 
primary tumour and/or metastases can be resected. However, a limitation to this approach 
is the inability to target melanoma in transit and/or detect microscopic metastases. For this 
reason, surgical resection is used in conjunction with radiation and/or systemic therapies, 
such as chemotherapy, targeted therapies and immunotherapies (Maverakis et al., 2015).  
Melanoma is known to be inherently resistant to currently used chemotherapeutic agents 
and radiation, requiring combination of these agents with other therapies (Pak et al., 2004). 
Proteins involved in the MAPK pathway have been key targets for therapy. There are 
currently only two clinically used B-RAF inhibitors that target mutant B-RAF: 
vemurafenib and dabrafenib, that block B-RAFV600E activity. The BRIM-2 Phase II multi-
center study with vemurafenib identified a response rate of 53% in patients with B-
RAFV600E metastatic melanomas, with a median duration of response of 6.7 months. 
Adverse effects included the development of cutaneous squamous cell carcinoma in 26% 
of patients, but these lesions were effectively managed by surgical removal (Sosman et al., 
2012). These effects were attributed to the activation of the MAPK pathway in 
keratinocytes with pre-existing RAS mutations (Su et al., 2012). In vitro studies have shown 
that inhibition of B-RAF in cells containing RAS mutations result in the dimerization and 
activation of C-RAF, followed by activation of MAPK signalling and enhanced growth 
(Hatzivassiliou et al., 2010; Poulikakos et al., 2010). The effectiveness of vemurafenib 
compared to dacarbazine, a commonly used drug to treat melanoma, was investigated in 
the BRIM-3 Phase III clinical trial. Overall median progression-free survival was 6.9 
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months for patients in the vemurafenib treatment and 1.6 for patients taking dacarbazine 
(Chapman et al., 2011), demonstrating the value of treating with vemurafenib in patients 
with metastatic melanomas containing BRAFV600E mutations.  
Similarly, dabrafenib has shown promising results in Phase I and II clinical trials with 59%-
69% of patients exhibiting clinical responses (Falchook et al., 2012; Ascierto et al., 2013). 
The Phase III BREAK-3 trials later demonstrated median progression-free survival of 5.1 
months for patients who received dabrafenib treatment, compared to 2.7 months for 
patients treated with dacarbazine (Hauschild et al., 2012). Unfortunately, due to the 
emergence of resistance to the B-RAF inhibitors, these clinical benefits have been short-
lived. In vitro studies with melanoma cells resistant to B-RAF inhibitors demonstrated 
sustained activation of the MAPK pathway through alternative mechanisms. For example, 
the kinase COT can activate the MAPK pathway in a MEK-dependent and RAF-
independent manner (Johannessen et al., 2010). Increased COT mRNA expression has also 
been observed in metastatic B-RAFV600E melanoma biopsies of individuals undergoing 
vemurafenib treatment, suggesting that COT may contribute to acquired resistance 
(Johannessen et al., 2010). Subsets of B-RAF inhibitor-resistant melanoma samples with 
increased expression of PDGFR and N-RAS mutations have also been identified (Nazarian 
et al., 2010). For these reasons, other members of the MAPK pathway have become 
additional targets for therapy.  
Trametinib is a clinically used MEK inhibitor. In a Phase III trial (METRIC) of patients 
with B-RAF-mutated metastatic melanoma, administration of trametinib resulted in  
median progression-free survival of 4.8 months, compared to 1.5 months for patients 
treated with dacarbazine (Flaherty et al., 2012). The side effect of developing cutaneous 
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squamous cell carcinoma as observed with B-RAF inhibitor treatment, was not observed 
in the individuals who were administered trametinib (Marzuka et al., 2015). To increase 
efficacy and reduce toxicity, combination therapy with both B-RAF and MEK inhibitors 
has been investigated. Phase III trials using B-RAF and MEK inhibitors have shown 
increased progression-free survival, response rate and overall survival with diminished  
adverse effects compared to B-RAF inhibitor monotherapy (Long et al., 2014; Larkin et 
al., 2014; Robert et al., 2015). B-RAF and MEK combination therapy has now been 
recommended as the standard-of-care for patients with BRAF-mutant melanoma.    
Immunotherapies harness the ability of the immune system to detect and target tumour 
cells following antigen presentation. T-cell activation occurs when T-cell receptors bind to 
an antigen presented on major histocompatibility complex (MHC) proteins. T-cell 
responses are further regulated by signals transduced through co-stimulatory and co-
inhibitory receptors (Grosso and Jure-Kunkel, 2013). Tumour cells can evade immune 
system responses by expressing ligands that bind to co-inhibitory receptors on T-cells. 
Upon T-cell activation, the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
receptor, is recruited to the T-cell membrane and participates in inhibition of T-cell 
function. Similarly, programmed death-1 (PD1) is a receptor found on the T-cell membrane 
with inhibitory T-cell function (Pedoeem et al., 2014) (Figure 1.4). Ipilimumab is a human 
IgG monoclonal antibody (mAb) that binds to the CTLA-4 receptor and when bound 
sterically hinders the binding of ligands to the receptor, thereby promoting T-cell activation 
(Marzuka et al., 2015; Ramagopal et al., 2017). Pembrolizumab and nivolumab are two 
human monoclonal antibodies, that function to block the PD-1 receptor. Clinical studies 
have shown improved overall survival in metastatic melanoma patients treated with  
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Figure 1.4. T-cell inactivation by tumour cells 
T-cells are activated when T-cell receptors (TCR) bind to antigens presented on major 
histocompatibility complex (MHC) proteins on antigen-presenting cells. Tumour cells can 
evade immune responses by expressing ligands that bind to co-inhibitory receptors on T-
cells, such as CTLA-4 and PD-1, resulting in T-cell inactivation. 
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ipilimumab, pembrolizumab or nivolumab (Hodi et al., 2010; Robert et al., 2011, 2014; 
Chmielowski et al., 2013). Additionally, patients receiving both ipilimumab and nivolumab 
displayed better overall survival compared to those receiving ipilimumab alone, indicating 
that there are additional benefits from combination therapy (Wolchok et al., 2017). Despite 
recent progresses in the treatment of metastatic melanoma, tumour cell resistance remains 
a major clinical challenge, and therefore there is pressing need to identify other therapeutic 
targets to overcome the emergence of resistance.  
1.6 Preclinical models used to study metastatic melanoma  
1.6.1 Human melanoma cell lines  
Numerous human melanoma cell lines have been used as models to understand human 
melanoma behaviour. A recent study compared the transcriptional profile of several of 
these cells lines with primary and/or metastatic melanoma tumours (Vincent and Postovit, 
2017). This study found that the expression of about 20, 000 protein-encoding genes was 
comparable between the melanoma cell lines examined and the tumours. Notably, 
differential expression was found in genes associated with immune function (Vincent and 
Postovit, 2017). This was considered an expected limitation of in vitro models that lack a 
microenvironment containing lymphatics, blood vessels and an extracellular matrix (ECM) 
(Sharma et al., 2015). Despite these limitations, because of the substantial degree of 
similarity in gene expression between melanoma cell lines and tumours, human melanoma 
cell lines remain useful models to study certain aspects of melanoma biology using cell 
culture approaches. 
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Currently there are numerous human metastatic melanoma cell lines such as SK-MEL-3, 
RPMI-7951, A375-MA2 and 131/4-5B1, that are being used to model metastatic 
melanoma. The A375-MA2 cell line was derived from lung metastases of the less 
metastatic parental A375 cell line (Xu et al., 2008; Chandrasekaran et al., 2016). Similarly, 
the 131/4-5B1, hereafter termed 5B1, cell line was derived from the human melanoma 
WM239A cells that acquired the ability to metastasize to the lungs and the brain (Cruz-
Munoz et al., 2008).  The 5B1 cells are particularly valuable tools for research, as very few 
melanoma cell lines with brain tropism in xenograft models have been isolated, and 
metastasis to the brain is associated with poor outcomes in individuals with melanoma 
(Sandru et al., 2014). Therefore, the 5B1 cells are an excellent preclinical model of 
spontaneous melanoma brain metastasis. Additionally, the 5B1 cells are resistant to 
vinblastine and cyclophosphamide, and can therefore model human metastatic melanomas 
that are similarly resistant to standard chemotherapeutic agents in the clinic.  
1.6.2 The chick chorioallantoic membrane (CAM) model 
The chick CAM is used to investigate tumour cell behaviour in an in vivo setting (Ribatti, 
2014; Deryugina and Quigley, 2009). The CAM lines the inner surface of the egg shell and 
is composed of two epithelial membranes termed chorionic and allantoic epithelium. These 
two membranes enclose the mesoderm, which contains blood vessels and extracellular 
matrix proteins. The CAM functions in gas exchange and is highly vascularized, hence it 
has been an excellent model to use in studies pertaining to angiogenesis (Cepeda et al., 
2016; Cheng et al., 2015; Zijlstra et al., 2007). Additionally, tumour cells can be grafted 
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onto the nutrient rich-CAM to investigate tumour formation and progression (Penuela et 
al., 2012; Li et al., 2015; Zuo et al., 2015).  
Previous studies have used the chick CAM to explore melanoma biology. The CAM 
supports the development of tumours formed from the mouse metastatic melanoma cell 
line, B16-F10 (Penuela et al., 2012; Ableser et al., 2014), with some studies specifically 
investigating B16-F10 tumour angiogenesis (Vandercappellen et al., 2010; Ribatti et al., 
2013; Yurlova et al., 2010). Similarly, the chick CAM was used to support tumour growth 
of human metastatic melanoma cells. A recent study grafted the A375 human metastatic 
melanoma cells into plastic rings placed on top of the chick CAMs to investigate tumour 
vessel density (Avram et al., 2017). The SK-MEL-2 melanoma cells were also inoculated 
into sterile plastic rings placed on CAMs, but to investigate the effects of 2 triterpenoids 
agents on vascular density surrounding the developing tumours (Caunii et al., 2017). 
Additionally, the chick CAM model has been used in metastasis assays where upon 
melanoma tumour formation on the CAM, chick organs such as the brain and liver, were 
harvested for isolation of genomic DNA and consequent detection of human melanoma 
cells by qPCR (Sinnberg et al., 2018).  
1.6.3 Mouse melanoma models  
Established mouse metastatic melanoma cells lines, such as the B16-F10 line, are also 
commonly used in melanoma research (Brown et al., 2002; Mummert et al., 2003; 
Winkelmann et al., 2006; Penuela et al., 2012). B16-F10 cells are a metastatic clone of the 
B16 mouse melanoma cells (Sharma et al., 2015) The B16 cells were passaged in vivo 
through tail vein injections, resulting in the formation of lung metastases, from which the 
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highly metastatic B16-F10 cells were isolated (Sharma et al., 2015). A limitation to the use 
of mouse melanoma cell lines to model human melanomas is the differences in the driving 
mutations found in human and mouse melanomas. While the majority of human 
melanomas acquire mutations in B-RAF, these mutations were not observed in any of the 
spontaneous or carcinogen-induced mouse melanoma cell lines analysed (Melnikova et al., 
2004). Additionally, all mouse melanoma cell lines expressed PTEN, suggesting that loss 
of PTEN is not involved in mouse melanoma formation (Melnikova et al., 2004). Similar 
to the use of human melanoma cell lines, in vitro culture experiments using mouse 
melanoma cell lines are limited in their ability to recapitulate tumour interactions with the 
stromal microenvironment (van der Weyden et al., 2016). To model tumour growth and 
metastasis in vivo, several mouse models have been developed, including those that involve 
syngeneic or xeno-transplantation of melanoma cells, and genetically engineered mouse 
models.  
Xenografts models involve the subcutaneous engraftment of patient-derived melanoma 
cells or tumour fragments (Einarsdottir et al., 2014), or of human melanoma cell lines in 
immunodeficient mice (Kleffel et al., 2015). Xenograft models are often used to explore 
tumour growth and metastasis, and to investigate therapeutic interventions (Fofaria and 
Srivastava, 2014; Yang et al., 2015).  Genetically engineered mouse models are frequently 
used to determine the effects of genetic alterations in the initiation and progression of 
melanoma. Mice have been genetically modified to mimic the B-RAFV600E or N-RASQ61K 
mutations. Melanocyte-specific tamoxifen inducible activation of BrafV600E in Tyr::CreER; 
BrafCA/+ mice only resulted in pigmented melanocytic lesions that did not progress to 
melanoma (Dankort et al., 2009). This phenotype was consistent with the concept that 
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melanocyte progression to melanoma requires several mutations in addition to BRAF 
driver mutations. The combination of B-RAF and PTEN alterations better modeled 
melanoma formation, as mice with loss of PTEN together with B-RAFV600E expression 
(Tyr::CreER; BrafCA; Ptenlox/lox mice) developed skin melanomas and metastases to the 
lymph nodes and lungs (Dankort et al., 2009). Similarly, transgenic mice with melanocyte-
specific tamoxifen inducible N-RASQ61K expression developed benign melanocytic 
lesions. However, the combination of melanocyte-specific p16INK4a gene inactivation with 
N-RASQ61K expression  (Tyr::NrasQ61K; INK4a-/- mice) resulted in melanoma formation 
and metastasis (Ackermann et al., 2005). These two transgenic lines have been extensively 
used to study melanoma biology (Lee et al., 2013; Durban et al., 2013; Hennessey et al., 
2017; Tormo et al., 2009).  
Mice expressing B-RAFV600E or N-RASQ61K have also been used to investigate the role of 
additional genetic alterations in melanomas (Damsky et al., 2011; Shah et al., 2010). For 
example, a recent study examined melanoma formation in mice with melanocyte-specific 
inactivation of the gene that encodes the non-receptor tyrosine kinase FES, together with 
Pten inactivation and B-RAFV600E expression (Tyr::CreER; BrafCA/+; Ptenfl/fl; Fes-/- mice) 
(Olvedy et al., 2017). In these animals, loss of FES expression resulted in accelerated 
melanoma formation and decreased overall survival, suggesting that FES likely functions 
as a growth suppressor in human melanoma (Olvedy et al., 2017). FES is also known to 
play a suppressive role in colorectal carcinoma cell anchorage-independent growth and 
many colorectal tumours express little or no detectable FES protein (Delfino et al., 2006).  
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FES and FER are members of the FES family of non-receptor tyrosine kinases. Although, 
the role of FES in melanoma has been investigated, the biological functions of FER in 
melanoma are not known and will be the focus of my study.  
1.7 FER kinase  
1.7.1 The FES family of non-receptor tyrosine kinases   
Non-receptor tyrosine kinases predominantly function within the cytoplasm of cells to 
transduce signals from various cell surface receptors to downstream effectors (Hubbard 
and Till, 2000). In humans, non-receptor tyrosine kinases are grouped into ten main 
families, which include FES, SRC, JAK, ABL, ACK, CSK, FAK, FRK, TEC and SYK 
(Robinson et al., 2000).  
The FES family is composed of two members, FES and FER (Robinson et al., 2000). 
Structurally, FES and FER consist of an amino-terminal F-BAR domain, followed by two 
coiled coil domains, a central SH2 domain and a carboxy-terminal tyrosine kinase domain 
(Figure 1.5). The conserved F-BAR domain can interact with negatively charged 
phospholipids on the cell membrane to promote lamellipodia formation and cellular 
migration (Itoh et al., 2009; McPherson et al., 2009). The SH2 domain mediates 
interactions with substrates containing phosphotyrosine residues, thereby regulating kinase 
activity. Finally, the tyrosine kinase domain is responsible for the catalytic activity of these 
enzymes (Greer, 2002). The amino terminus coiled coil domains are required for the 
oligomerization of FER (Craig et al., 1999). FER oligomerization promotes 
autophosphorylation in trans however, it is not essential for kinase activation (Orlovsky et  
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Figure 1.5. FER kinase protein domains 
FER kinase is comprised of an amino terminus F-BAR domain followed by two coiled coil 
domains, a SH2 domain and a carboxy terminus tyrosine kinase domain. The F-BAR 
domain consists of the conserved FCH domain and the first coiled-coil (CC) domain. 
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al., 2000; Craig et al., 1999). The amino terminus is also involved in the regulation of FER 
kinase activity by interacting with other proteins, such as plectin which inhibits FER 
autophosphorylation (Lunter and Wiche, 2002).  
FES has been detected in haematopoietic myeloid lineages, vascular endothelium, 
epithelial cells, neurons and melanocytes (Haigh et al., 1996; Care et al., 1994; Greer et al., 
1994; Easty et al., 1995). FES-null mice are viable and fertile, but exhibit increased 
activation of the transcription factors, STAT3 and STAT5, in response to interleukin-6 (IL-
6) cytokine and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Hackenmiller et al., 2000) and increased sensitivity to lipopolysaccharide (LPS) exposure 
(Zirngibl et al., 2002), suggesting that FES is involved in innate immune responses, and is 
necessary for normal myeloid and macrophage function.   
In humans, the FER locus is on chromosome 5q.21 and encodes a ubiquitous 94-kDa 
protein (Robinson et al., 2000). FER can localize to both the cytoplasm and nucleus (Hao 
et al., 1991; Ben-Dor et al., 1999).  In mice, there is a testes-specific FER transcript, termed 
FerT, which encodes a truncated 51-kDa protein expressed in primary spermatocytes. FER 
and FerT share the SH2 and kinase domains; however, they differ in their amino terminus 
(Fischman et al., 1990; Keshet et al., 1990). FerT has also recently been reported to localize 
to the mitochondria of human colon carcinoma cells (Makovski et al., 2012a; Yaffe et al., 
2014). Directed mitochondrial expression of FerT in non-malignant fibroblast cells 
resulted in the formation of tumours in vivo, suggesting that FerT may play a novel pro-
tumourigenic role (Yaffe et al., 2014).  
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1.7.2 FER kinase protein-protein interactions  
In the cytoplasm, FER is involved in signal transduction and has been shown to interact 
with and phosphorylate EGFR and PDGFR (Kim and Wong, 1995; Guo and Stark, 2011; 
Lennartsson et al., 2013). Stimulation of mouse fibroblasts or A431 human squamous 
carcinoma cells by EGF or PDGF resulted in the formation of FER-p120 catenin 
complexes, in which the coiled coil domains of  FER associates with p120 catenin (Kim 
and Wong, 1995). FER weakens adherens junctions through phosphorylation of β-catenin, 
which prevents its interaction with α-catenin (Piedra et al., 2003; Rosato et al., 1998). 
Conversely, FER phosphorylation of the tyrosine phosphatase PTP1B stabilizes adherens 
junctions by facilitating PTP1B dephosphorylation of β-catenin (Xu, 2004).  In sum, FER 
modulates adherens junctions and cell-cell adhesion through its association with several 
proteins.   
Stimulation of various cell types by growth factors also promotes phosphorylation of the 
actin-binding protein cortactin by FER (Kim and Wong, 1998). Cortactin is involved in 
regulating actin dynamics, as it can bind to the Arp2/3 complex and stabilize branched 
filamentous actin (Weaver et al., 2001). In addition, phosphorylated cortactin is necessary 
for migration in various cell types, including mouse melanoma (Huang et al., 1998; Bryce 
et al., 2005; Huang et al., 2003).  In response to actin depolymerization by latrunculin B, 
there is increased association between FER and cortactin and increased phosphorylation of 
cortactin (Fan et al., 2004), suggesting that FER may be involved in regulating actin 
dynamics through its interaction with cortactin.  
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FER indirectly plays a role in lamellipodia dynamics through its interactions with Rho 
GDP-dissociation inhibitor (RhoGDI). Lamellipodia formation is necessary for the 
initiation of directional cell migration and involves various proteins including RAC1 
(Steffen et al., 2013). Inactive RAC1 remains in the cytoplasm bound to RhoGDI, however, 
activation of RAC1 by guanine nucleotide exchange factor (GEF) and dissociation from 
RhoGD1 allows for the translocation of RAC1 to the cell membrane and consequent 
interaction with its downstream effectors (Moissoglu et al., 2006). Of the three RhoGDI 
isoforms,  RhoGDIα can be phosphorylated by and forms a complex with FER (Fei et al., 
2010). This phosphorylation disrupts RhoGDIα binding to RAC1, thereby promoting 
RAC1 localization to the cell membrane (Fei et al., 2010; Hodge and Ridley, 2016).  
FER kinase is also involved in insulin signalling. The activation of the insulin receptor 
results in the phosphorylation of IRS1. IRS1 can then bind to and activate PI3K, resulting 
in activation of other downstream effectors involved in the PI3K signalling pathway  
(Boucher et al., 2014). Upon insulin stimulation of adipocytes, FER associates with 
complexes containing IRS1 and PI3K, promoting insulin-mediated signal transduction 
within the cell (Iwanishi et al., 2000; Iwanishi, 2003).  
The in vivo biological functions of FER kinase have been examined using knock-in mice 
with kinase-inactivating FER mutations (Craig et al., 2001). These mice develop normally, 
display no obvious phenotypical alterations and are fertile, thereby suggesting that FER 
kinase activity is not essential for development or survival. The formation of adherens 
junctions or focal adhesions and EGF or PDGF-induced phosphorylation of p120 catenin 
and β-catenin does not require FER kinase activity. Cortactin phosphorylation however, 
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was reduced in embryonic fibroblasts isolated from these mice, indicating that FER plays 
an important role in the regulation of cortactin phosphorylation (Craig et al., 2001).  
1.7.3 The role of FER kinase in human tumours  
FER is involved in multiple biological processes associated with tumour formation and 
progression. Specifically, prostate, renal, bladder urothelial, lung and ovarian carcinoma 
cells exhibit increased FER expression relative to normal cells in those tissues (Allard et 
al., 2000; Miyata et al., 2013; Hu et al., 2017; Ahn et al., 2013; Fan et al., 2016). FER 
expression is an independent predictor of survival among patients with renal, bladder 
urothelial, ovarian and breast cancer, with high FER expression associated with poor 
prognosis (Miyata et al., 2013; Hu et al., 2017; Fan et al., 2016; Ivanova et al., 2013).  
FER promotes the proliferation of prostate, breast, renal and colon carcinoma cells through 
various mechanisms (Allard et al., 2000; Pasder et al., 2006; Miyata et al., 2013; Makovski 
et al., 2012b). For example, in prostate carcinoma cells, FER promotes cell cycle 
progression through RB-mediated mechanisms (Pasder et al., 2006). Specifically, FER 
phosphorylates the RB phosphatase PP1α and downregulation of FER in prostate cells 
results in increased activation of PP1α, which dephosphorylates RB. The hypo-
phosphorylated form of RB inhibits cell proliferation.  Additionally, FER forms complexes 
with and phosphorylates STAT3 and the androgen receptor upon IL-6 induction in prostate 
carcinoma cells, resulting in the transcription of genes associated with cell proliferation 
and survival (Zoubeidi et al., 2009; Rocha et al., 2013). Furthermore, FER silencing in 
colon carcinoma cells disrupts cell cycle progression and initiates programmed cell death 
through activation of ATM and its downstream effector p53 (Makovski et al., 2012b). FER 
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deficiency in primary breast carcinoma cells results in increased EGF-induced EGFR 
internalization and amplification of the MAPK signalling pathway, paradoxically resulting 
in cytostasis due to supranormal activation of the EGFR pathways (Sangrar et al., 2015). 
In vivo studies have also demonstrated delayed tumour onset and decreased tumour cell 
proliferative capacity of FER-deficient breast tumours (Sangrar et al., 2015).  
FER has also been shown to mediate resistance to quinacrine, which is a therapy that 
induces cell apoptosis through inhibition of NF-κB and activation of p53. Overexpression 
of FER in lung and colon carcinoma cells, results in increased activation of NF-κB and 
increased phosphorylation of EGFR and ERK in the absence of EGF, resulting in the 
activation of genes responsible for cell survival and proliferation (Guo and Stark, 2011).  
FER kinase has been shown to promote the migratory capacity of tumour cells. In prostate 
and breast carcinoma cells, FER reduces the expression of laminin-binding glycans, 
thereby impairing attachment of cells to the extracellular matrix and promoting cell 
migration (Yoneyama et al., 2012). The absence of FER interferes with the process of 
epithelial-mesenchymal transition (EMT) in bladder urothelial carcinoma cells, through 
mechanisms that involve increased expression of E-cadherins, together with decreased 
expression of N-cadherins, Slug and Snail (Hu et al., 2017). FER-deficient lung carcinoma 
cells also display decreased migration, due to impaired EGF-induced lamellipodia 
formation. This impairment is due to decreased phosphorylation of the GEF Vav2, 
resulting in decreased Vav2-RAC1 activity, reduced lamellipodia formation and cell 
migration (Ahn et al., 2013). In FER-deficient breast carcinoma cells, decreased motility 
and invasion are due to increased cell adhesion to the ECM due to elevated β1and α6 
integrin levels, promoting focal adhesion formation. Breast carcinoma cells in which FER 
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is silenced are also more susceptible to anoikis (programmed cell death due to detachment 
from the ECM) (Ivanova et al., 2013).  
FER increases the invasive capacity of bladder urothelial, hepatocellular, breast, lung and 
ovarian carcinoma cells (Hu et al., 2017; Li et al., 2009; Ivanova et al., 2013; Ahn et al., 
2013; Fan et al., 2016). FER-deficient bladder urothelial cells exhibit decreased invasion 
due to decreased matrix metalloproteinase (MMP) expression (Hu et al., 2017) and FER-
deficient lung carcinoma cells are less invasive due to impaired lamellipodia formation 
(Ahn et al., 2013). Recently a novel signalling pathway involving FER kinase was shown 
to promote motility and invasion of ovarian carcinoma cells (Fan et al., 2016). Specifically, 
FER can phosphorylate the receptor tyrosine kinase MET in the absence of ligand binding 
to this receptor, leading to the phosphorylation of the adaptor protein GAB1 and the 
tyrosine phosphatase Shp2. These events in turn result in activation of the RAC1 and 
MAPK pathways, which potentiate cell motility and invasiveness (Fan et al., 2016).  
Several studies on FER and cancer cell metastasis have used mouse xenograft models. 
Sections of mouse organ tissues were analysed for the presence of tumour cells, indicating 
cell metastasis from the primary tumour. The spontaneous formation of metastases from 
FER-deficient breast, lung and ovarian tumours to distant organs was decreased, suggesting 
that FER promotes metastasis in these tumour cell types (Ivanova et al., 2013; Ahn et al., 
2013; Fan et al., 2016). 
The above studies suggest that targeted inhibition of FER activity may attenuate tumour 
growth and/or metastasis. Recently, a small molecule inhibitor of FER and FerT kinase 
activity named E260 was developed using a yeast-based high-throughput screening system. 
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In colon carcinoma cells, FER and PARP-1 association was disrupted following E260 
treatment, causing increased PARP-1 activity and a consequent increase in autophagy. 
Additionally, treatment of colon, liver, and pancreas carcinoma cells with E260, resulted 
in selective mitochondrial deformation and dysfunction, resulting in decreased cellular 
ATP levels. This energy deficit further induced cellular autophagy. Additionally, systemic 
E260 treatment of mice with colon carcinoma cell xenografts resulted in decreased tumour 
volume, and histopathological analysis demonstrated necrotic and non-vascularized 
tumour tissue (Elkis et al., 2017).  
This above study demonstrates the pro-tumourigenic effects of FER in various carcinoma 
cells and the attenuation of these effects following inhibition of FER kinase activity using 
E260. The therapeutic potentials of E260 further demand the investigation of the role of 
FER in other cancers, such as melanoma.  
1.8 Rationale, hypothesis and aims 
In human colorectal and melanoma cancer, FES has been shown to play a tumour 
suppressive role. However, FER, the other protein family member, plays a pro-
tumourigenic role in numerous cancers. This suggests that FER and FES may function in 
opposite manners during tumourigenesis. The biological functions of FER in human 
metastatic melanoma have not been explored, and observation of FER function in others 
cancers suggest that FER may promote melanoma tumourigenesis. I hypothesize that FER 
kinase contributes to the tumourigenic properties of human melanoma cells. To test this 
hypothesis, the specific aims of my study are:  
1. Determine the role of FER kinase in human melanoma cell proliferation.  
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2. Investigate the role of FER kinase in melanoma cell susceptibility to apoptosis.  
3. Determine the role of FER kinase in human melanoma cell migration.  
4. Examine the role of FER kinase in human melanoma cell invasion.  
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Chapter 2  
2 Materials and methods  
2.1 Reagents  
Table 2.1: Reagents 
Reagent Source Catalogue No. 
Amersham ECL Prime 
Western Blotting Detection 
Reagent  
GE Healthcare, 
Mississauga, ON 
RPN2232 
Aprotinin BioShop, Burlington, ON APR200 
Bio-Rad Protein Assay Dye 
Reagent Concentrate  
Bio-Rad, Mississauga, 
ON 
5000006 
5-bromo-2’-deoxyuridine Acros Organics, Belgium 22859-5000 
Collagen Type 1, rat tail  Corning, Bedford, MA 354236 
Cultrex Basement Membrane 
Matrix, Type 3 
Trevigen, Gaithersburg, 
MD 
3632-001-02 
Doxycycline hydrochloride Fisher Scientific, Whitby, 
ON 
BP26531 
Eosin Y Sigma-Aldrich, Oakville, 
ON 
HT11016 
Fetal bovine serum (FBS) Gibco, Burlington, ON 12483-020 
Hoeschst 33342 Life Technologies, 
Burlington, ON 
H1399 
Leupeptin Bioshop, Burlington, ON LEU001 
Mayer’s hematoxylin Sigma-Aldrich, Oakville, 
ON 
MHS16 
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NaF Sigma Aldrich, St. Louis, 
MO 
S7920 
Na3VO4 Bioshop, Burlington, ON SOV664 
Paraformaldehyde (PFA) Fisher Scientific, Whitby, 
ON 
AC416780030 
Pepstatin Bioshop, Burlington, ON PEP605 
Permount Mounting Medium Fisher Scientific, Ottawa, 
ON 
SP15-100 
Phenylmethylsulfonylfluoride 
(PMSF)  
Bioshop, Burlington, ON PMS123 
Poly-L-lysine (PLL) 
hydrobromide solution 
Sigma Aldrich, St. Louis, 
MO 
P5899 
Rhodamine-labeled Lens 
Culinaris Agglutinin (LCA) 
Vector Laboratories, 
Brockville, ON 
VECTRL1042 
RPMI 1640 with L-glutamine 
and sodium bicarbonate  
Sigma-Aldrich, Oakville, 
ON 
R8758 
Shandon Immu-Mount 
mounting medium 
Thermo Fisher Scientific, 
Pittsburgh, PA  
2860060 
TGX Stain-Free FastCast 
Acrylamide Kit, 7.5% 
Bio-Rad, Mississauga, 
ON 
1610181 
Triton X-100 EMD, Darmstadt, 
Germany  
CATX-1568 
Trypsin, 2.5% Gibco, Burlington, ON 15090046 
Tween-20 Amresco, Solon, OH 0777 
Xylene Anachemia, Montreal, 
QB 
97233-540 
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2.2 Materials  
Table 2.2: Materials 
Material Source Catalogue No. 
Axygen, 1.5-ml Eppendorf 
tubes 
Corning, Bedford, MA 10011-700 
BioLite T25-cm2 Flasks, 
Cell Culture Treated  
Thermo Fisher Scientific, 
Rockford, IL 
130189 
BioLite T75-cm2 Flasks, 
Cell Culture Treated  
Thermo Fisher Scientific, 
Rockford, IL 
130190 
BioLite T175-cm2 Flasks, 
Cell Culture Treated  
Thermo Fisher Scientific, 
Rockford, IL 
130191 
CELLSTAR Tissue 
Culture Dishes, 60 x 15 
mm 
VWR Scientific, Radnor, 
PA 
82050-546 
Conical tubes, 15-ml Sarstedt, Numbrecht, 
Germany  
62.554.205 
Conical tubes, 50-ml Sarstedt, Numbrecht, 
Germany 
62.547.205 
Embedding cassettes VWR Scientific, Radnor, 
PA 
CA60830-098 
Falcon conical tubes, 15-
ml  
BD Biosciences, Bedford, 
MA 
352097 
Glass coverslips, 12mm, 
No. 1 
VWR Scientific, Radnor, 
PA 
031014-9 
Greiner Bio-One 6-well 
cell culture plates  
VWR Scientific, Radnor, 
PA 
82050-842 
Greiner Bio-One 24-well 
cell culture plates 
VWR Scientific, Radnor, 
PA 
82050-892 
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Imaging dish, 35 mm μ-
Dish 
Ibidi, Madison, WI 81156 
Immobilon-P membrane 
(PVDF) transfer 
membranes, 0.45-μm pore 
size   
EMD Millipore, Billerica, 
MA 
IPVH00010 
Micro cover glass, 
rectangular, 22 x 50 mm 
VWR Scientific, Radnor, 
PA 
48393-059-1 
Nunclon 4-well 
MultiDishes 
VWR Scientific, Radnor, 
PA 
CA62407-068 
Syringe filter, 0.2 μm Sardtedt, Nümbrecht, 
Germany 
83.1826.001 
Teflon cell scraper Thermo Fisher Scientific, 
Waltham, MA 
08-100-240 
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2.3 Antibodies  
Table 2.3: Antibodies 
Antibody Source Catalogue No. Dilution a 
AlexaFluor 488- 
conjugated goat 
anti-chicken IgG 
(H+L) 
Life Technologies, 
Burlington, ON 
A-11039 IHC: 1:500 b 
AlexaFluor 555- 
conjugated goat 
anti-mouse IgG 
(H+L) 
Life Technologies, 
Burlington, ON  
A-21422 IF, IHC:1:500 b 
AlexaFluor 555- 
conjugated goat 
anti-rabbit IgG 
(H+L) 
Life Technologies, 
Burlington, ON 
A-21428 IF: 1:500 b 
AlexaFluor 647-
conjugated goat 
anti-mouse IgG 
(H+L) 
Life Technologies, 
Burlington, ON 
A-21449 IHC: 1:500 b 
5-bromo-2’-
deoxyuridine 
(BrdU) 
Developmental 
Studies Hybridoma 
Bank, Iowa City, IA 
G3G4 IF: 1:500 b 
Cleaved caspase 3 Cell Signalling 
Technology, 
Pickering, ON 
9661S IB: 1:1000 c 
Collagen Type 3  Developmental 
Studies Hybridoma 
Bank, Iowa City, IA 
3B2 IHC: 1:6 b 
FER kinase  Cell Signalling 
Technology, 
Pickering, ON 
4268S IB: 1:1000 d 
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γ-tubulin Sigma, St. Louis, 
MO 
T6557 IB: 1:10 000 e 
GFP Abcam, Cambridge, 
MA 
13970 IHC: 1:1000 b 
HRP-conjugated 
goat anti-mouse IgG 
Jackson 
ImmunoResearch, 
West Grove, PA 
115-038-003 IB: 1:500 f 
HRP-conjugated 
goat anti-rabbit IgG 
Cell Signalling, 
Pickering, ON 
7074 IB: 1:500 f 
Ki67 Abcam, Cambridge, 
MA 
15580 IF: 1:200 b 
Pmel17 Santa Cruz, Dallas, 
TX 
sc-377325 IF: 1:50 b  
IHC: 1:100 b 
a  IB: immunoblot  
   IF: immunofluorescence   
IHC: immunohistochemistry  
b diluted in 1x PBS containing 5% goat serum, for one hour at 22 °C 
c diluted in 1x TBST containing 5% nonfat milk, overnight at 4 °C   
d diluted in 1x TBST containing 1% BSA, overnight at 4 °C   
f diluted in 1x TBST containing 5% nonfat milk, for one hour at 22 °C  
e diluted in 1x TBST containing 1% BSA, 30 minutes at 22 °C  
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2.4 Preparation of poly-L-lysine (PLL)-coated glass coverslips  
Glass coverslips were washed in 1M HCl for 5 h at 50-60° C. They were cooled to room 
temperature and then washed with 100% ethanol and dried in the tissue culture laminar 
flow hood. The coverslips were then incubated with a solution containing 0.1 g/ml of PLL 
dissolved in 18-MΩ dH2O for 1 h at 22 °C. They were then washed with deionized dH2O 
and allowed to dry in the tissue culture laminar flow hood. The coverslips were stored in a 
sterile container until used.  
2.5 Preparation of poly-HEMA coated dishes  
Poly-HEMA solution was made by adding 1.2 g of poly-HEMA to 99.5% (vol/vol) ethanol 
and dissolving it for 5-6 h at 37 °C, as described in (Kuroda et al., 2013). CELLSTAR 
tissue culture dishes, 60 x 15 mm, were coated with 1.3 ml of this solution and allowed to 
dry overnight in the tissue culture laminar flow hood. Coated plates were stored at 22 °C 
for up to 1 month.  
2.6 Laminin 332 matrix production, collection and coating 
procedures  
The laminin 332 matrix producing 804G cells (Tripathi et al., 2008) were cultured in RPMI 
1640 medium with L-glutamine and 5% FBS. Once 804G cells reached 90% confluency, 
the culture medium was removed by aspiration, the cells were washed once with PBS and 
then cultured in serum-free RPMI 1640 medium. Fourty-eight hours later, conditioned 
medium was collected and centrifuged at 130 x g for 5 min at 22 °C. The supernatant 
38 
 
containing laminin 332 matrix was filtered through a 0.2 μm syringe filter and stored at 
4°C for up to 1 week.  
μ-Dishes were coated with 8.6 μg/cm2 of collagen I (diluted in 0.02 M acetic acid) for 16 
h at 22 °C. The dishes were then washed thoroughly with PBS before plating cells. To coat 
dishes with laminin 332 matrix, 2 ml of the laminin 332-containing 804G conditioned 
medium was placed in the dish and incubated at 37 °C for 1.5 h. The medium was aspirated 
and cells were plated. For experiments involving collagen I and laminin 332, dishes were 
sequentially coated with collagen I and laminin 332-matrix, following the steps described 
above for the individual extracellular matrix substrates.   
2.7 Cell culture and doxycycline treatments    
131/4-5B1 cells (Cruz-Munoz et al., 2008), hereafter referred to as 5B1 cells, were a kind 
gift from Dr. Robert Kerbel (Sunnybrook Health Sciences Centre, Toronto, ON, Canada). 
A doxycycline (dox)-inducible and lentivirus-based small hairpin RNA (shRNA) system 
(Herold et al., 2008) was used to downregulate FER kinase levels in these cells. Lentivirus 
transductions were conducted by Dr. Iordanka Ivanova as follows. The third generation 
lentivirus packaging plasmids, pHDM.Hgpm2 (which encodes gag-pol), pHDM.G 
encoding VSV-G, pREV and pTat, were a kind gift from Dr. Patrick Derksen (University 
Medical Center Utrecht, The Netherlands). 293T cells were transfected with these 
plasmids, together with either FH1tUTG control, non-targeting or FH1tUTG FER-
targeting shRNA plasmids (Ivanova et al., 2013). In this manner, transfected cells were 
able to package lentiviral particles encoding the appropriate shRNAs. Lentivirus-
containing medium was collected 72 h after transfection, centrifuged at 130 x g for 5 min 
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and filtered through a 0.45-μm filter. The lentiviruses were then re-suspended in RPMI 
1640 medium containing 5% FBS and added to 5B1 cells to transduce them. GFP-positive 
cells were subjected to fluorescence activated cell sorting (FACS), cultured and used in all 
subsequent experiments as polyclonal melanoma cell populations. The lentivirus-mediated 
integration of the control (non-targeting) or the FER-targeting shRNA into the genome of 
the parent 5B1 cells generated two new cell lines, hereafter termed, respectively, Control 
and FER 9 cells. The FER shRNA targets positions 594 - 614 in the FER kinase mRNA, 
which correspond to the F-BAR domain of the protein. The nucleotide sequences for the 
Control, non-targeting shRNA, are as follows:  
Control sense:  
5’-tcccttctccgaacgtgtcacgtttcaagagaacgtgacacgttcggagaatttttc-3’  
Control anti-sense:  
5’-tcgagaaaaattctccgaacgtgtcacgttctcttgaaacgtgacacgttcggagaa-3’ 
The nucleotide sequences for the FER-targeting shRNA are as follows, with the targeting 
sequences being capitalized:  
FER[978-998] sense:  
5’-tcccGTATTATGATATCACACTTCCttcaagagaGGAAGTGTGATATCATAATACtttttc-3’  
FER[978-998] anti-sense:  
5’-tcgagaaaaaGTATTATGATATCACACTTCCtctcttgaaGGAAGTGTGATATCATAATAC-3’ 
Control and FER 9 5B1 cells were cultured in RPMI 1640 medium with L-glutamine and 
5% fetal bovine serum (FBS). A stock solution of doxycycline (dox) was made by 
dissolving dox in dH2O to a concentration of 1 mg/ml.  To silence FER mRNA and 
decrease FER protein levels, cells were cultured in the presence of 2 μg/ml of dox for 5 
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days. Medium was changed every 48 hours and fresh dox was added to maintain shRNA 
expression, resulting in decreased FER kinase levels. Each experiment was conducted with 
Control and FER 9 cells treated with 1X PBS (vehicle) or with dox. Cells were cultured at 
37°C in a humidified atmosphere containing 5% CO2. 
To investigate the duration of FER knockdown following dox removal, 5B1 cells were 
cultured in medium containing 2 μg/ml of dox for 5 days, after which the cells were washed 
with PBS and further cultured with fresh medium without dox. Cells remained in culture 
for up to 7 days after dox withdrawal. FER levels were measured every day by immunoblot 
analysis as outlined in section 2.11.  
804G rat bladder epithelial cells secrete laminin-332-containing matrix (Langhofer et al., 
1993). Therefore, the laminin 332 matrix produced by these cells was used in cell migration 
studies, as outlined in section 2.6. 804G cells were cultured in RPMI 1640 medium with 
L-glutamine and 5% FBS at 37 °C in a humidified atmosphere containing 5% CO2. 
2.8 Analysis of cell proliferation  
Cells plated at a density of 2.0x104 cells/cm2 on PLL-coated glass coverslips were 
incubated in growth medium containing 10 μM of 5’-bromo-2-deoxyuridine (BrdU) for 2 
h at 37 °C. The cells were then fixed and processed for immunofluorescence microscopy, 
as described in section 2.12. Fixed cells were incubated with mouse anti-BrdU antibody 
(Section 2.3), washed thrice with PBS (10 min/wash) and then incubated with secondary 
goat anti-mouse AlexaFluor 555-conjugated IgG for 1 h, protected from light.   
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Similarly, cells plated at a density of 2.0x104 cells/cm2 on PLL-coated glass coverslips 
were fixed and incubated with rabbit anti-Ki67 antibody (Section 2.3), washed thrice with 
PBS (10 min/wash) and then incubated with secondary goat anti-rabbit AlexaFluor 555-
conjugated IgG for 1 h, protected from light.   
2.9 Apoptosis and anoikis analysis  
Cells were plated at a density of 3.6 x 103 cells/cm2 on 60-cm culture dishes with or without 
poly-HEMA coating. Six days after plating, the cells were collected and processed for 
immunoblotting as outlined in section 2.11, to determine cleaved caspase-3 levels. In order 
to demonstrate that 5B1 cells were susceptible to apoptosis, adherent control 5B1 cells 
were treated with 80 μM or 100 μM of cisplatin. And to induce apoptosis in another cell 
type, adherent 804G cells were irradiated with 75 mJ of UVC light. Cells were collected 
and processed according to Section 2.11.  
2.10 Cell motility assays  
Cells were plated on extracellular matrix coated 35-mm μ-Dishes (prepared according to 
section 2.6) at a density of 8.6 x 103 cells/cm2. Images were acquired over a 16-h period 
using an EVOS Cell Imaging System (ThermoFisher Scientific), capturing a phase-contrast 
image every 10 min. Image sequences were imported into ImageJ (NIH) and the Manual 
Tracking Plug-in was used to track every cell within the frame. Migration tracks were then 
analyzed using the Chemotaxis and Migration Tool software (ibidi), where the migration 
path of each cell was visually outlined, and the accumulated (total) distance, the euclidean 
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distance (straight linear distance from the initial to the final migration point) and the 
average speed of each cell were calculated.  
2.11 Immunoblot analysis  
2.11.1 Preparation of cell lysates 
Growth medium was removed from culture dishes by aspiration, and the cells were rinsed 
once with ice-cold PBS. One ml of PBS was added and a Teflon cell scraper was used to 
gently scrape the cells from the culture dish. The cell suspension thus obtained was then 
transferred to a 1.5-ml microfuge tube and centrifuged at 5 000 x g for 5 minutes at 4°C. 
After centrifugation, the supernatants were removed by aspiration and the cell pellets were 
either immediately processed or stored at - 20°C to process at a later time.  
Cell pellets were resuspended in 50 μl of ice-cold lysis buffer (50 mM Tris pH 7.6, 150 
mM NaCl, 1% Triton X-100, 1 mM PMSF, 5 mM Na3VO4, 1 μg/ml aprotinin, 1 μg/ml 
pepstatin, 1 μg/ml leupeptin) and incubated on ice for 30 min. The lysates were then 
centrifuged at 13 400 x g for 10 min at 4°C. Following centrifugation, supernatants were 
transferred to new microfuge tubes. The protein concentration in each lysate was 
determined using the Bradford assay. Lysates were either immediately processed or stored 
at – 20 °C to process at a later time.  
2.11.2 Polyacrylamide gel electrophoresis and immunoblot analysis  
Cell lysate samples were prepared with 50 μg of protein, lysis buffer and 6x Laemmli 
loading buffer (1.2g SDS, 6 mg bromophenol blue, 4.7 ml glycerol, 1.2 ml of 0.5M Tris 
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pH 6.8, 0.93 g DTT and 2.1 ml 18-MΩ H2O) and then denatured by heating to 99°C for 5 
minutes. For FER kinase analysis, 7.5% polyacrylamide gels were made, using the TGX 
Stain-Free FastCast Acrylamide Kit. For cleaved caspase-3 analysis, samples were 
resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), using 12% resolving 
and 5 % stacking polyacrylamide gels. 
Resolved proteins were then transferred onto a 0.45-μm pore size hydrophobic immobilon-
P polyvinylidene difluoride (PVDF) membrane using a semi-dry transfer apparatus. 
Membranes were blocked by gentle rocking in Tris buffered saline containing 0.1% Tween 
20 (TBST, 100 mM Tris-HCl pH 7.5, 1.5 M NaCl) and 5% nonfat milk for 1 h at 22 °C.  
Following a 10-min wash in TBST, the membranes were incubated with primary antibody 
diluted in TBST at the dilutions specified in section 2.3. After probing with primary 
antibody, the membranes were washed three times (10 min/wash) with TBST and then 
incubated with the species-specific, horse-radish peroxidase-conjugated secondary 
antibody diluted in 5% nonfat milk in TBST solution. Following the secondary antibody 
incubation, the membranes were washed 3 times with TBST (10 min/wash).  
Proteins were detected using 1:1 vol/vol of Amersham ECL Prime Western Blotting 
Detection Reagent and images were acquired using a VersaDoc Imaging System (Bio-Rad) 
and Quantity One software (version 4.6.9). To quantify protein levels, densitometric 
analyses were conducted using Quantity One software, by drawing equally sized 
rectangular regions of interest over the background and the bands quantified. A volume 
report consisting of volume, area and density of bands was provided by the software. The 
density of the background was subtracted from the densities of the bands of interest. 
Proteins levels were normalized to those of γ-tubulin to correct for differences in protein 
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loading, and normalized protein levels are presented relative to control conditions in all 
relevant experiments.  
2.12 Immunofluorescence microscopy  
Cells were fixed with freshly diluted 4% paraformaldehyde (PFA) in PBS for 20 min at 22 
°C and washed three times with PBS (10 min/wash). They were then permeabilized with 
0.1% Triton X-100 solution in PBS for 20 min and then washed twice with PBS (10 
min/wash). In experiments to detect BrdU incorporation, genomic DNA was denatured by 
incubating the cells with 2M HCl for 20 min at 22°C. The cells were then thoroughly 
washed three times with PBS (10 minutes/ wash) at 22°C. All samples were blocked with 
PBS containing 5% non-fat milk for 1 h at 22 °C with gentle rocking. After three washes 
with PBS (10 min/wash), the cells were incubated with appropriate primary antibodies 
(anti-BrdU, anti-Ki67 or anti-Pmel17) as described in section 2.3. The cells were then 
washed three times with PBS (10 min/wash) and incubated for 1 h with the appropriate 
AlexaFluor-conjugated secondary antibody. Cells were washed thrice with PBS (10 
min/wash) and were then incubated with Hoechst 33342 for 5 min protected from light. 
Following three 10-min washes with PBS, the samples were mounted onto microscope 
slides using Immu-mount mounting medium.  Slides were allowed to dry overnight 
protected from light and imaged using a Leica DMIRBE fluorescence microscope (Leica 
Microsystems, Wetzlar, Germany) equipped with an Orca-ER digital camera (Hamamatsu 
Photonics, Hamamatsu, Japan) and Volocity 4.3.2 software. 
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2.13 Chorioallantoic Membrane (CAM) experiments  
2.13.1 Chicken embryo incubation  
Fertilized chicken eggs (McKinley Hatchery, St. Mary’s Ontario) were incubated in a 
rotary incubator (Berry Hill) at 70% humidity at 37°C for 3 days, after which the eggs were 
cracked and all contents, including the embryos at day-4 of development, were placed into 
a weighing boat. Each weighing boat was covered with a plastic lid allowing air circulation, 
housed in a holed plastic container containing autoclaved water and maintained in a 
stationary incubator set at 70% humidity and 37°C for a week. The incubator facilities and 
cracking procedures were kindly provided by Dr. Silvia Penuela and her personnel 
(Department of Anatomy and Cell Biology). On day 11 of development, one week after 
cracking, 1.5 x 106 5B1 cells re-suspended in 30 μl of Cultrex Basement Membrane Matrix 
were placed gently on a branching vascular point of the chick chorioallantoic membrane 
(CAM). The embryos were then returned to the stationary incubator. Seven days post-
inoculation, on day 18 of development and just prior to harvesting, rhodamine labeled lens 
culinaris agglutinin (LCA) (1:10 dilution of a 5 mg/ml stock in PBS), was injected into the 
CAM vasculature by Dr. Mario Cepeda, who kindly helped with this step in the 
experiments. Immediately after LCA injection, tumours with their surrounding CAM were 
excised and placed in 4% PFA overnight for further processing.  
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2.13.2 Tissue sectioning 
 Excised tumour samples were processed (dehydrated and immersed in paraffin wax) at the 
Molecular Pathology Core Facility at The Robarts Research Institute and tissues were 
sectioned (7 μm in thickness) by Mr. Kevin Barr.  
2.13.3 Immunohistochemistry analyses  
Paraffin-embedded sections were dewaxed and rehydrated by placing them in the following 
reagents for 5 min each: twice in xylene followed by 100% and 95% ethanol. The slides 
were then washed twice with deionized water (2 min per wash).  For hematoxylin and eosin 
staining, the slides were first placed in Mayers Hematoxylin for 2 min then washed with 
tap water for 1 min. Slides were then placed in tap water containing 200 μl of 1M NaOH 
for 1 min, washed under running tap water for 5 sec, then dipped into 70% ethanol for 30 
sec and placed in Eosin Y for 2 min. Next, they were sequentially placed in two staining 
jars containing 70% ethanol, 1 min in each jar. Slides were dehydrated by sequential 
immersion in the following solutions: 95% ethanol, 100% ethanol, and then 2 xylene 
staining jars (1 min per jar). Coverslips were mounted onto the slides, using Permount.  
For immunostaining, high-temperature antigen retrieval was conducted by immersing the 
tissue sections in boiling sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, 
pH 6.0) for 30 min. The sections were then incubated with primary antibody diluted in PBS 
containing 5% goat serum for 1 h and then washed 3 times with PBS. Next, the sections 
were incubated for 1 h with the appropriate AlexaFluor-conjugated secondary antibody 
diluted in PBS containing 5% goat serum. Following 3 washes with PBS, nuclear DNA 
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was stained with Hoechst 33342 (1:10 000 dilution of a 10 μg/ml stock in PBS) for 5 min, 
protected from light. The sections were washed three additional times before mounting 
using Immu-mount medium.   
5B1 cells were detected in the CAM section using a chicken anti-GFP antibody followed 
by goat anti-chicken AlexaFluor 488-conjugated secondary antibody. CAM tissues were 
visualized using a mouse anti-Collagen type III antibody, which specifically recognizes 
chicken tissues, followed by the goat anti-mouse AlexaFluor 647-conjugated secondary 
antibody. Fluorescence images were acquired as described in section 2.12.  
2.14 Statistical analyses  
GraphPad Prism software (version 6.0) was used for all statistical analyses. Unpaired t-test 
was applied for two-way comparisons, and one-way analysis of variance (ANOVA) 
followed by Tukey’s post-hoc test was used for multiple comparisons. Significance was 
set at P values < 0.05. Unless otherwise indicated, all experiments were conducted at least 
three times, using 3 technical replicates for analysis.  
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Chapter 3  
3 Results  
3.1 Characterization of Control and FER 9 human 
melanoma cells 
To investigate the role of FER kinase in melanoma biology, I used a silencing approach in 
5B1 human melanoma cells, with a doxycycline-inducible lentivirus-based shRNA system. 
Upon stable integration of FER-targeting shRNA sequences into genomic DNA, and 
subsequent transcription following doxycycline (dox) treatment, FER kinase levels can be 
reduced. The shRNA vectors used also contain a GFP-encoding cassette, allowing for 
FACS selection of GFP-positive cells. Therefore, transduced 5B1 cells can be identified 
through GFP fluorescence imaging. Phase-contrast and fluorescence images from passage 
1 (P1) Control cells and cells with the inducible FER shRNA (hereafter termed FER 9) 
were acquired, demonstrating that every cell in the phase-contrast image was also GFP-
positive (Figure 3.1A). This shows that both Control and FER 9 cells were successfully 
transduced with their respective shRNA, to generate polyclonal populations.  
To analyse GFP expression in the 5B1 cells upon dox treatment, Control and FER 9 cells 
were treated with or without dox for 5 days and then examined using fluorescence imaging. 
The heterogeneity of the Control and FER 9 polyclonal populations accounts for the 
observed differences in GFP expression from one cell to the next. However, all Control 
cells were GFP-positive, indicating that dox administration does not affect GFP expression. 
Similarly, all FER 9 cells, irrespective of FER protein levels, were GFP-positive (Figure  
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Figure 3.1. FER kinase knockdown of Control and FER 9 cells 
Control and FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 
days. A. Phase contrast and fluorescence images were acquired to confirm GFP expression. 
B. FER protein levels of cells at passages 1, 5 and 10 were analysed by immunoblot. 
Histograms represent mean protein levels ± SEM (N=3) normalized to γ-tubulin (to correct 
for protein loading) and are expressed relative to Control -dox values, which are set to 1. * 
represents P < 0.05 relative to Control -dox cells, and & indicates P < 0.05 relative to FER 
9 -dox (ANOVA). Scale bar = 70 μm.  
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3.2). To reaffirm that the observed GFP expression is specific to the 5B1 melanoma cells, 
immunofluorescence imaging for premelanosome protein (Pmel) expression was 
performed. Pmel is a melanocyte-lineage specific type I transmembrane glycoprotein that 
is mainly located in immature melanosomes Therefore, it is commonly used to detect 
melanoma cells (Theos et al., 2005). Every GFP-positive Control and FER 9 cell, in Figure 
3.2, is correspondingly Pmel-positive indicating that the observed GFP expression is 
specific to the 5B1 melanoma cells. In addition, no differences in Pmel expression were 
observed in the Control and FER 9 cells (Figure 3.2).  
To determine FER levels in Control and FER 9 cells, P1 cultures were treated with or 
without dox for 5 days and FER kinase levels were measured by immunoblotting. FER 9 
cells treated with dox exhibited about a 90% decrease in FER protein levels compared to 
untreated FER 9 cells (Figure 3.1B). Control cells showed no significant differences in 
FER kinase levels irrespective of the presence or absence of dox. In addition, there was no 
significant difference in FER levels between Control cells and FER 9 cells in the absence 
of dox. This demonstrates an inducible system, in which only upon doxycycline treatment 
an efficient reduction in FER kinase levels is observed specifically in cells transduced with 
FER-targeting shRNA sequences.  
I next examined if the inducible nature of the system is maintained throughout cell 
passaging. Transduced P5 and P10 cells were imaged and FER kinase levels were 
measured in these cultures. All cells observed were GFP-positive at both P5 and P10, 
indicating that GFP expression is stable over this period in culture (Figure 3.1A). Dox-
treated FER 9 cells showed about an 88% and 65% decrease in FER levels at P5 and P10, 
respectively (Figure 3.1B). In addition, there was no significant difference in FER levels  
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Figure 3.2. Melanocytic lineage confirmation of GFP-positive 5B1 cells 
Control and FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 
days. Immunofluorescence microscopy with an anti- premelanosome (pmel) antibody was 
used to demonstrate the melanocytic lineage of GFP positive 5B1 cells. White bar = 140 
µm.  
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between Control cells and untreated FER 9 cells. This demonstrates that FER kinase levels 
can be efficiently reduced in 5B1 clones at least as late as P10. Consequently, all 
experiments in these studies were conducted with cells between P1 and P5 in which FER 
9 cells treated with dox consistently showed an 80-90% decrease in FER protein levels.  
To investigate the duration of FER knockdown after dox withdrawal, Control and FER 9 
cells were cultured in medium containing dox for 5 days, after which the cells were washed 
and cultured with fresh medium without dox. The cells were then cultured for 7 days in the 
absence of dox and FER levels were measured by immunoblot analysis. Figure 3.3 shows 
that FER levels remained decreased by 63-85% during the 7 days post-dox treatment. This 
demonstrates that following 5 days of dox treatment, FER kinase levels remain 
significantly reduced for at least 7 days. In addition, no significant differences were found 
in the FER protein levels of Control cells in the 7-day time period, indicating that FER 
levels were not affected by previous dox treatment.   
3.2 Effects of FER knockdown on cell proliferation  
To determine the effects of reduced FER kinase levels on proliferation, Control and FER 
9 cells were cultured in medium containing dox for 5 days and then processed for 
immunofluorescence microscopy to analyze the fraction of cells expressing Ki67. During 
interphase of the cell cycle, the Ki67 protein can be found in the nucleus of cells and during 
mitosis it can be found on the surface of chromosomes (Scholzen and Gerdes, 2000). 
Therefore, Ki67 can be used to detect actively proliferating cells (i.e. cells in phases G1, 
S, G2 and M, but not in G0). Through immunofluorescence microscopy I found that, 69 ±  
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Figure 3.3. Duration of FER kinase knockdown after dox removal in 5B1 cells 
Control and FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 
days. Cultures were then rinsed and incubated with dox-free growth medium. FER levels 
were measured using immunoblot analysis at the indicated times following dox removal. 
Histograms represent mean FER protein levels ± SEM (N=3) normalized to γ-tubulin and 
expressed relative to Control -dox or FER 9 -dox cells, which are set to 1. “Day” indicates 
the number of days following dox removal and the “Dox” labelling indicates whether cells 
were pretreated with dox.  * represents P < 0.05 relative to FER 9 -dox cells (ANOVA). 
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8% and 70 ± 15% of Control cells without and with dox, respectively, were Ki67-positive. 
In addition, 73 % ± 13 % of FER 9 cells without dox and 83 ± 5% FER 9 cells with dox 
were Ki67-positive (Figure 3.4). Therefore, no significant differences were identified 
suggesting that FER-expressing and FER-deficient cells were actively proliferating.  
Although Ki67 is an excellent global marker of proliferating cells, it does not allow for the 
investigation of cell cycle phase-specific differences between cell populations. Therefore, 
I opted to determine if S-phase differences result from FER kinase knockdown. Control 
and FER 9 cells were treated with dox for 5 days after which cells were incubated in 
medium containing 5-bromo-2-deoxyuridine (BrdU), a thymidine analog that is 
incorporated into DNA during S-phase. I then determined the proportion of cells showing 
BrdU immunoreactivity and found that 24 ± 3% and 30 ± 4% of Control cells had 
incorporated BrdU into their DNA in cultures in the presence and absence of dox, 
respectively. Therefore, no significant differences in Control cells occurred as a 
consequence of dox treatment (Figure 3.5). In contrast, whereas the proportion of BrdU-
positive FER 9 cells cultured without dox was 29 ± 3%, only 17 ± 4% of FER 9 cells were 
found to be BrdU-positive when FER was silenced by dox treatment (Figure 3.5). 
Consequently, FER-deficient cells exhibit a 41% decrease in the proportion of cells in the 
S-phase of the cell cycle, thereby suggesting that FER kinase plays a role in normal 
melanoma cell cycle progression.  
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Figure 3.4. Effect of FER kinase silencing on 5B1 expression of Ki67 
Control and FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 
days and then processed for immunofluorescence microscopy, using an anti-Ki67 
antibody. The histogram represents the fraction of Ki67-positive cells in each cell group, 
expressed as the mean ± SEM (N=3). Scale bar = 140 μm.   
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Figure 3.5. Effect of FER kinase silencing on 5B1 cells in S-phase 
Control and FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 
days then incubated in medium containing 10 μM of BrdU for 2 h. The cells were processed 
for immunofluorescence microcopy using an anti-BrdU antibody. The histogram 
represents the fraction of BrdU-positive cells, expressed as the mean ± SEM (N=3). * 
represents P< 0.05 (ANOVA). Scale bar = 140 μm. 
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3.3 Effect of FER kinase silencing on 5B1 susceptibility to 
anoikis  
To investigate the effect of FER kinase knockdown on cell susceptibility to anoikis, a form 
of apoptosis due to detachment from the extracellular matrix, Control and FER 9 cells were 
cultured in the presence of dox for 5 days and then plated on normal culture dishes, which 
allowed cell adhesion, or on dishes coated with poly-HEMA, which prevented cell 
adhesion to their surface, and thus maintained cells in suspension, for 6 days. Anoikis was 
analysed by immunoblotting for the presence of the early apoptosis marker, cleaved-
caspase 3. Cleaved-caspase 3 was not detected in either FER-expressing or FER-deficient 
cells plated on either adherent or suspension conditions (Figure 3.6). As a positive control 
for apoptosis, cleaved caspase 3 was readily detected in adherent Control cells treated with 
80 or 100 μM of cisplatin, as well as in G804 rat epithelial bladder cells that were irradiated 
with 75 mJ of UVC light. This demonstrates that neither Control nor FER 9 cells were 
susceptible to anoikis irrespective of whether they express FER kinase.  
3.4 Effects of FER knockdown on random 5B1 cell motility  
In the skin, human melanoma cells metastasize through various mechanisms, including 
interactions with extracellular matrix proteins such as collagen I (Col I) and laminin 332 
(Lam 332). Therefore, I next determined 5B1 random cell motility on these ECM 
substrates. Control cells were cultured on uncoated μ-Dishes or on dishes coated with Col 
I, Lam 332 or both. Cells were then imaged for 16 h using time-lapse video microscopy. 
All cells within the field of view were then tracked to measure migration distance and 
velocity. Figure 3.7A illustrates migratory cell paths 
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Figure 3.6. FER kinase knockdown on 5B1 cell susceptibility to anoikis 
Control and FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 
days and then plated on dishes coated with (suspended cells) and without (adherent cells) 
poly-HEMA. As a positive control for 5B1 cell death, adherent Control cells were treated 
with 80 and 100 μM of cisplatin and adherent G804 cells were irradiated with 75 mJ of 
UVC as a different cell type control for apoptosis. The presence of cleaved-caspase 3 in 
cell groups was detected by immunoblot analysis (N=3). 
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(indicated by closed circles) on the different ECM substrates, as well as, in the absence of 
exogenously added ECM. The majority of cells cultured with no exogenous matrix or on 
collagen I, showed minimal migration from their initial point of tracking (0,0). Specifically, 
in the absence of exogenous ECM the cells migrated a total distance of 182 ± 18 μm, with 
a speed of 0.19 ± 0.02 μm/min, whereas cells cultured on Col I migrated a total distance of 
179 ± 21 μm with a speed of 0.19 ± 0.02 μm/min. In contrast, the migration paths of cells 
cultured on Lam 332 illustrate movement away from their initial positions. After 16 h, 
these cells displayed a total migration distance of 278 ± 22 μm, with a speed of 0.28 ± 0.02 
μm/min (Figure 3.7). Therefore, a 53% increase in total migration and 47% increase in 
speed were observed in the cells when plated on Lam 332. Cells cultured on dishes coated 
with both collagen I and laminin 332 displayed no significant difference in migration or 
speed, 220 ± 11 μm and 0.23 ± 0.01 μm/min, respectively. Another measure of migration, 
the Euclidean distance, is a linear measure of the distance between the initial and final 
migration positions and can therefore be used to quantify directionality in migration. No 
significant differences were found in the Euclidean distances of Control cells cultured on 
no ECM, Col I, Col I and Lam 332 and Lam 332, 64 ± 10 μm, 65 ± 17 μm, 61 ± 8 μm and 
83± 7 μm, respectively. Thus, irrespective of exogenous ECM, Control cells maintained 
their normal random migration. In summary, only the addition of exogenous Lam 332 
promotes random 5B1 cell migration.  
Next, to determine the effects of FER kinase silencing on migration on Lam 332, Control 
and FER 9 cells were cultured with dox for 5 days and then plated on dishes coated with 
Lam 332. Cells were imaged for 16 h using time-lapse video microscopy, and the distance 
and speed were measured as above. The migration paths of FER-expressing cells, as  
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Figure 3.7. 5B1 migration on different extracellular matrices 
Untreated Control cells were plated on μ-Dishes without any exogenous extracellular 
matrix (No ECM) or coated with collagen I (Coll), laminin 332 (Lam332) or both (C&L). 
Cells were imaged for 16 h using time-lapse video microscopy and analysed using Image 
J (NIH) and the Chemotaxis and Migration Tool Software (ibidi). Two hundred cells were 
tracked in total for each cell group.  A. Migratory paths of Control cells on varying 
extracellular matrices. The initial migratory point of a cell is represented as (0,0) and the 
final point is illustrated as a closed circle. B.  Histograms represent mean ± SEM (N=3) 
accumulated (total) distance, Euclidean distance (straight linear distance from the initial to 
final migratory point) and speed of Control cells. * represents P < 0.05 (ANOVA).  
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illustrated in Figure 3.8A, show that in general their final positions were farther removed 
from the origin compared to FER-deficient cells. Control cells cultured in the absence of 
dox migrated a total distance of 278 ± 38 μm with a speed of 0.28 ± 0.04 μm/min, whereas 
Control cells treated with dox similarly migrated a total distance of 274 ± 80 μm with a 
speed of 0.32 ± 0.04 μm/min. Thus, dox treatment per se had no significant effect on cell 
motility. Similarly, FER 9 cells cultured in the absence of dox migrated a total distance of 
330 ± 23 μm with a speed of 0.35 ± 0.02 μm/min. In contrast, silencing of FER caused a 
significant decrease in cell motility, as FER 9 cells treated with dox migrated 228 ± 54 μm 
with a speed of 0.25 ± 0.07 μm/min (Figure 3.8B). This difference corresponds to a 31% 
decrease in total distance and a 29% decrease in the migratory speed of FER-deficient cells. 
The Euclidean distances of Control (no dox: 83 ± 7 μm, dox: 92 ± 15 μm) and FER 9 (no 
dox: 102 ± 6 μm, dox: 78 ± 12 μm) cells were not significant, indicating random migration 
of the cells irrespective of their levels of FER. Therefore, the downregulation of FER 
impairs random cell migration indicating that FER kinase is essential for normal melanoma 
cell migration on Lam 332.  
3.5 The chicken chorioallantoic membrane (CAM) in vivo 
tumour xenograft model to study tumour invasion  
Analysis of tumour growth, invasion, and metastasis in vivo are often explored using mouse 
models or the chicken CAM. The CAM is found just underneath the surface of the egg 
shell and plays a vital role in gas exchange. It is composed of two epithelial membranes, 
the outermost membrane is called the chorionic epithelium, whereas the innermost 
membrane, located closer to the chicken embryo, is the allantoic epithelium. These two 
membranes enclose the mesoderm, which is a highly vascularized stromal tissue containing  
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Figure 3.8. Effect of FER kinase knockdown on 5B1 motility 
Control and FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 
days and then cultured on μ-Dishes coated with laminin 332. Cells were imaged for 16 h 
using time-lapse video microscopy and analysed using Image J (NIH) and the Chemotaxis 
and Migration Tool Software (ibidi). Three hundred cells were tracked in total for each cell 
group.  A. Migratory paths of FER-expressing and FER-deficient cells on laminin 332. The 
initial migratory point of a cell is represented as (0,0) and the final point is illustrated as a 
closed circle. B.  Histograms represent mean ± SEM (N=3) accumulated (total) distance, 
Euclidean distance (straight linear distance from the initial to final migratory point) and 
speed of cells. Dot plot illustrates the distribution of 5B1 accumulated distance, Euclidean 
distance and speed values. * represents P < 0.05 (ANOVA).   
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various extracellular matrix proteins, such as type III collagen. In chicks, CAM growth 
begins on embryonic day (E) 3 and is completed by E10 (Nowak-Sliwinska et al., 2014). 
In the CAM tumour xenograft model, fertilized chicken eggs are cracked and their contents 
are placed in covered dishes. The CAM is then easily accessible for experiments involving 
grafting of cells or addition of test substances onto the CAM (Figure 3.9A).  
To determine if 5B1 cells can form tumours on the CAM, untreated FER 9 cells suspended 
in Cultrex extracellular matrix extract were grafted onto the CAMs of E11 chick embryos 
that were isolated by cracking in the manner described above. Seven days post-grafting, 
rhodamine-labelled lens culinaris agglutinin (LCA) was injected into a blood vessel of the 
CAM and 5-10 min after, the tumours and underlying CAM tissues were harvested and 
processed for analysis. LCA labels endothelial cells (Deryugina and Quigley, 2009), thus 
allowing for visualization of the CAM vasculature. Figure 3.9B shows 5B1 tumour growth 
on the chorionic epithelium of the CAM, indicating that 5B1 cells suspended in Cultrex 
can grow and form tumours that are readily visible 7 days post-grafting. Immunostaining 
was then conducted on these tumour sections to determine the best way to distinguish 5B1 
cells from CAM tissue. 5B1 cells were clearly visible based on GFP-immunoreactivity, 
and could be effectively distinguished from the CAM, which was labelled using an 
antibody that specifically recognizes chicken collagen type III (Melkonian et al., 2000) 
(Figure 3.9C). The identity of the GFP-positive Control and FER 9 melanoma cells in 
xenografts was further confirmed by the presence of Pmel, as every GFP-positive cell in 
tumour tissue also expressed Pmel (Figure 3.9D). I also observed GFP-negative regions 
within the tumour, which may constitute necrotic tumour tissue. The presence of chicken 
endothelial cells, indicative of vasculature within the CAM and the tumour was observed,  
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Figure 3.9. Illustration of the chicken chorioallantoic membrane (CAM) used to 
measure 5B1 cell invasion 
FER 9 cells were cultured in medium with or without 2 μg/ml of dox for 5 days. Cells 
suspended in Cultrex were grafted on the CAMs of embryonic day 11 (E11) embryos and 
incubated for an additional 7 days to allow for tumour growth. On E18, rhodamine labelled 
lens culinaris agglutinin (LCA) was injected into a blood vessel of the CAM, tumours were 
excised and processed for further analysis. A. Schematic of 5B1 tumour growth on the 
CAM. BV= blood vessel. B. Representative hematoxylin and eosin (H&E) stained tumour 
tissue section showing 5B1 tumour growth and invasion into CAM mesoderm. Black Bar 
= 100 μm. The area outlined by the black rectangle is represented in C. as fluorescence 
images demonstrating 5B1 cell detection using GFP immunoreactivity and detection of the 
CAM using a chicken specific collagen III antibody. Shown in red, are the endothelial cells 
labelled with rhodamine-LCA. White bar = 100 μm. D. GFP and Pmel immunoreactivity 
in Control and FER 9 tumour tissue to confirm the melanocytic lineage of GFP-positive 
5B1 cells. White bar = 64 μm.  
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based on staining by the rhodamine-labelled LCA, which is known to bind to 
glycoconjugates on the endothelial lining of blood vessels (Figure 3.9C).  
3.6 Comparison of 5B1 tumour growth in Matrigel and Cultrex 
Matrigel (Corning) and Cultrex (Trevigen) are mixtures of extracellular matrix proteins 
secreted by the Engelbreth-Holm Swarm (EHS) mouse sarcoma. They are composed of 
about 60% laminin, 30% collagen IV and 8% entactin, as well as sulfate proteoglycans and 
growth factors (Kleinman and Martin, 2005). Matrigel has been frequently used in 
xenograft experiments (Benton et al., 2011). To compare tumour growth of 5B1 cells 
suspended in Matrigel or in Cultrex, untreated Control and FER 9 cells were suspended in 
one of these substrates and grafted onto the CAM of E11 chick embryos. Seven days after 
grafting, the tumours and underlying CAMs were harvested and processed for analysis. 
Control and FER 9 cells were able to form tumours on the CAM when suspended in either 
Matrigel or Cultrex.  5B1 cells were also detectable within the CAM tissue, as evidenced 
by the presence of GFP immunoreactivity within collagen III-positive CAM tissue (Figure 
3.10). 5B1 tumour growth in Matrigel was indistinguishable from that in Cultrex. For all 
subsequent experiments in this study, cells were suspended in Cultrex. 
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Figure 3.10. Capacity of Matrigel and Cultrex matrices to support 5B1 tumour 
growth 
Untreated Control and FER 9 cells were suspended in either Matrigel or Cultrex and then 
grafted on the CAMs of E11 embryos. Tumours were excised on E18 and processed for 
immunohistochemistry analysis. A. H & E stained sections of tumours formed from 5B1 
cells suspended in Matrigel or Cultrex. T= tumour, black bar = 215 µm. B. GFP and 
collagen III antibodies were used to detect 5B1 cells and delineate the CAM, respectively. 
T= tumour, C= CAM, black bar = 108 µm and white bar = 100 µm.  
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3.7  Analysis of 5B1 cell invasion into the CAM mesoderm 
To systematically characterize 5B1 tumour growth and invasion, sections throughout the 
tumour were analyzed. The sections selected were obtained from three areas: near the edge 
of the tumour, schematically represented by (A) on Figure 3.11, in the middle of the tumour 
(C, Figure 3.11) and between those two regions (B, Figure 3.11). On average, Control and 
FER 9 tumours were about 5 mm wide. The distance between the regions indicated as A 
and B in the schematic was about 0.4 mm, whereas the boundaries indicated as B and C 
were approximately 2 mm apart. GFP-positive melanoma cells were detected in the 
sections analyzed from regions A, B and C (Figure 3.11). Invasion into the CAM 
mesoderm, evidenced by the presence of GFP immunoreactivity embedded within collagen 
III-positive areas, was also observed in these sections. As melanoma cell growth was 
consistently observed in these tumour areas, further analysis focused on the core region of 
the tumour located between regions A and C. For these studies, 10 tissue sections evenly 
distributed between regions A and C were analysed for each tumour, as previously 
performed by (Lokman et al., 2012).  
3.8 Effect of FER kinase silencing on 5B1 cell invasion into 
the CAM mesoderm  
To determine the role of FER kinase in 5B1 cell invasion into the CAM mesoderm, FER 9 
cells were first cultured in medium with or without dox for five days. The cells were rinsed 
to remove dox, suspended in dox-free Cultrex and grafted onto the CAM as described in 
section 3.5. Tumours were processed and ten 7-µm sections between regions A and C, 
(Figure 3.11) were analysed, as mentioned above. Figure 3.12 shows images obtained from  
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Figure 3.11. Systematic analysis of 5B1 cell invasion into the CAM mesoderm 
5B1 cell invasion into the CAM was characterized by analysing sections throughout the 
tumour. GFP and collagen III immunofluorescence was performed on sections obtained 
from the edge of the tumour (A), middle of tumour (C) and between those two regions (B). 
White bar = 100 µm. The white dotted line outlines the tumour-CAM interface.    
 
 
 
 
 
 
 
 
  
77 
 
  
78 
 
  
79 
 
Figure 3.12. Analysis of 5B1 invasion into the CAM mesoderm in ten sections of a 
FER-expressing tumour 
Untreated FER 9 cells suspended in Cultrex were grafted on the CAMs of E11 embryos 
and then cultured for 7 days to promote tumour growth. On E18, rhodamine-labeled lens 
culinaris agglutinin (LCA) was injected into a blood vessel of the CAM, the tumour was 
subsequently excised and processed for further analysis. Ten serial sections from between 
regions A and C were examined (Figure 3.11). Sections illustrating GFP immunoreactivity 
within collagen III-positive areas were categorized as sections showing 5B1 cell invasion. 
White bar = 64 µm.  The white dotted line outlines the tumour-CAM interface.  
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each of ten sections of a tumour formed by untreated FER 9 cells. In this specimen, sections 
1 through 6 show the presence of GFP-positive 5B1 cells within the collagen III-labeled 
CAM, indicative of invasion. On that basis, the tumour in Figure 3.12 received an invasion 
score of 6 out of 10. Notably, in this tumour, blood vessels were observed in close 
proximity to melanoma cells located within the CAM, as evidenced by the rhodamine-LCA 
fluorescence adjacent to and/or surrounding the GFP positive cells within the CAM. In 
addition, sections 8 through 10 displayed tumour growth on the CAM surface, and no blood 
vessels were detected within this tumour region. Similarly, for each tumour analyzed, the 
number of sections in which invasion was observed was scored.  
The invasion of FER-deficient tumours was then analyzed. Figure 3.13 illustrates the 10 
sections analysed for a tumour formed by FER 9 cells previously treated with dox (i.e. 
FER-deficient cells). In this tumour, cell invasion into the CAM mesoderm was observed 
in sections 1 and 7 through 10, therefore this tumour received an invasion score of 5 out of 
10. Similar to the tumour formed by untreated FER 9 cells (Figure 3.12), the presence of 
vasculature in close proximity to the melanoma cells within the CAM suggests that FER 
kinase is not essential for the ability of melanoma cells to localize proximal to blood 
vessels. The tumour sections No. 3 to 6 illustrate tumour cells growing on the CAM. In 
addition, sections No. 4 and No. 5 exhibit the presence of lectin-labelled chick endothelial 
cells within the tumour (Figure 3.13).  
In total, I grafted 49, 41, 52 and 54 CAMs with Control, Control with dox, FER 9 and FER 
9 with dox cells, respectively. The total number of tumours excised at the end of the CAM 
experiments are outlined in Table 3.1.  Of those, the indicated number of “viable” tumours  
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Figure 3.13. Analysis of 5B1 invasion into the CAM mesoderm in ten sections of a 
FER-deficient tumour 
Treated FER 9 cells (previously cultured in medium containing dox for 5 days) suspended 
in Cultrex were grafted onto the CAMs of E11 embryos and then cultured for 7 days to 
promote tumour growth. On E18, rhodamine-labeled lens culinaris agglutinin (LCA) was 
injected into a blood vessel of the CAM, the tumour was subsequently excised and 
processed for further analysis. Ten serial sections from between regions A and C were 
examined (Figure 3.11). Sections illustrating GFP immunoreactivity within collagen III-
positive areas were categorized as sections showing 5B1 cell invasion. White bar = 64 µm.  
The white dotted line outlines the tumour-CAM interface. 
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were analyzed. Tumour specimens were categorized as “viable” if they exhibited GFP 
immunoreactivity and Hoechst 33342 immunostaining revealed large round nuclei. 
Conversely, tumours were classified as necrotic if the cells found above the Collagen III-
positive CAM were not GFP-positive and exhibited irregularly shaped condensed 
chromatin. The invasion scores of the viable tumours are presented in Figure 3.14. 
Tumours from untreated and dox-treated Control cells have average invasion scores of 2 
and 4, respectively. Additionally, tumours formed from untreated FER 9 cells have an 
average invasion score of 2, whereas FER-deficient tumours (formed from previously dox-
treated FER 9 cells) have an average score of 7. This suggests that decreasing levels of 
FER in 5B1 cells do not impair the capacity of these cells to invade into the chick CAM 
mesoderm.  
Table 3.1: Characteristics of excised tumours * 
 Control Control with dox FER 9 FER 9 with dox 
Total tumours 
excised 
18 12 23 11 
Tumours analyzed 
(“Viable” tumours) 
7 10 10 10 
“Necrotic” tumours 11 2 13 1 
* Of the total tumours excised, only viable tumours were analyzed. Tumour specimens were classified as 
“viable” if they exhibited GFP immunostaining and even nuclear DNA staining patterns based on Hoechst 
33342-fluorescence. Tumours were classified as “Necrotic” if they exhibited condensed chromatin 
characteristics of non-viable cells, if they were found above and outside of the collagen III-positive CAM 
tissues and did not exhibit any detectable GFP immunoreactivity.   
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Figure 3.14. Effect of FER kinase on 5B1 cell invasion into the CAM mesoderm 
The dot plot illustrates the invasion scores (number of tumour tissue sections, out of 10, 
showing invasion) of Control and FER 9 tumours. The black lines indicate the average 
invasion score for each cell group and each black symbol represents a tumour of that cell 
group. 
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To evaluate the effects of FER kinase on endothelial cell localization to the tumour, FER 
9 cells pretreated with or without dox were suspended in Cultrex and grafted onto the CAM, 
as described in section 3.5. The tumour-specific regions, identified as regions not 
expressing collagen III, of the tumour sections were analysed for rhodamine-LCA 
fluorescence, indicative of endothelial cells. Specifically, 6 out of 7 tumours formed from 
untreated FER 9 cells and 5 out of 5 tumours formed from treated FER 9 cells showed 
endothelial cells within the tumour (Figure 3.15). Therefore, localization of endothelial 
cells within the tumour occurred in both the FER-expressing and FER-deficient tumours, 
indicating that FER is not essential for endothelial cell recruitment to the tumour.  
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Figure 3.15. Effect of FER kinase on endothelial cell localization to the tumour 
Tumour-specific regions, identified as areas not expressing collagen III, of FER 9 tumours 
were analysed for rhodamine-LCA fluorescence. White bar = 64 µm. The white dotted line 
outlines the tumour-CAM interface. 
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Chapter 4  
4 Discussion 
4.1 Summary 
FER kinase contributes towards the tumourigenic properties of various cancers, including 
breast (Sun et al., 2011), lung (Ahn et al., 2013) and prostate (Allard et al., 2000); however 
its role in human melanoma has not been explored. This study examined the contributions 
of FER to proliferation and invasion of human melanoma cells. I showed that FER 
silencing in 5B1 cells is associated with a decrease in the proportion of cells in S-phase of 
the cell cycle, suggesting that FER is essential for normal cell cycle progression. In 
addition, I observed a decrease in the migration of FER-deficient cells seeded on laminin 
332. My ex ovo CAM studies demonstrated that downregulation of FER resulted in 
increased 5B1 cell invasion into the CAM mesoderm and that FER is dispensable for the 
localization of endothelial cells to xenografted tumours.  
4.2 FER kinase modulates cell cycle progression  
Early subcellular fractionation experiments established that FER kinase localized to both 
the cytoplasm and the nucleus in various human carcinoma cells (Hao et al., 1991). 
Significantly, the nuclear localization of FER was found to change depending on the phase 
of the cell cycle. For example, in quiescent primary mouse fibroblasts, FER is cytoplasmic, 
and it translocates to the nucleus at the start of and throughout S-phase (Ben-Dor et al., 
1999). Similarly, FER nuclear translocation during S-phase was observed in human PC-3 
prostate carcinoma cells (Allard et al., 2000). Additionally, flow-cytometry and BrdU-
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incorporation studies demonstrated that the downregulation of FER kinase in the PC-3 cells 
caused an increase in the G0/G1 fraction, with a concomitant decrease in S-phase cells. 
This observation was attributed to the hypo-phosphorylation of CDK2 and CDK4, resulting 
in the hypo-phosphorylation of retinoblastoma protein (RB) and consequent activation of 
its repressing activity in the transcription of genes associated with proliferation (Pasder et 
al., 2006). These studies suggest that FER translocation to the nucleus is likely important 
for proper progression from G1 to S-phase. Similarly, in the present study, I have shown a 
decrease in the proportion of S-phase 5B1 melanoma cells following FER downregulation. 
Although, I did not investigate the role that changes in FER subcellular localization plays 
on 5B1 cell cycle progression, it will be important in future experiments to exogenously 
express FER kinase mutants lacking the nuclear localization signal in FER-deficient cells, 
to determine if these mutants modulate the ability of the cells to reach and traverse S-phase 
and, consequently, progress through the cell cycle.  
FER kinase also regulates the activity of several transcription factors implicated in cell 
proliferation. For example, in prostate carcinoma cells, STAT3 phosphorylation by FER is 
essential for STAT3 activation, nuclear localization and overall proliferation (Zoubeidi et 
al., 2009). In A375 melanoma cells, inhibition of STAT3 decreased proliferation (Flashner-
Abramson et al., 2016), suggesting that STAT3 plays an important role in melanoma 
growth. The interaction between FER and STAT3 in 5B1 cells will be an important area 
for further investigation.  
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4.3 5B1 cell susceptibility to anoikis  
Anoikis is a form of programmed cell death induced by detachment from the extracellular 
matrix. Signals from the microenvironment are important for cellular differentiation, 
survival, proliferation and migration. Untransformed epithelial and endothelial cells 
undergo anoikis when detached from the extracellular matrix (Rennebeck et al., 2005). 
However, many tumour cells, such as those in breast (Eckert et al., 2004) and prostate 
(Sakamoto and Kyprianou, 2010) carcinoma, are able to survive without attachment. This 
contributes to tumour progression, invasion into surrounding tissues and metastasis to 
secondary sites. Anoikis resistance likely arises from constitutive activation of pro-survival 
signalling pathways, alterations in integrin expression and changes in cell metabolism 
(Paoli et al., 2013).  
Melanoma cells have also been found to resist anoikis through various mechanisms. For 
example, B-RAF knockdown or MEK inhibition in WM793 melanoma cells cultured in 
suspension led to an increase in cleaved caspase-3 levels, a marker of apoptosis, and 
increased levels of two proapoptotic proteins, Bad and Bim (Boisvert-Adamo and Aplin, 
2006, 2008). Therefore, the B-RAF signalling pathway and its downstream effectors, Bim 
and Bad, modulate the susceptibility of WM793 melanoma cells to apoptosis. Other 
proteins, such as Myeloid Cell Leukemia-1 (Mcl-1) (Boisvert-Adamo et al., 2009) and 
STAT3, contribute towards melanoma resistance to anoikis. Interestingly, anoikis-resistant 
melanoma cells exhibit increased STAT3 phosphorylation and increased expression of the 
anti-apoptotic proteins Bcl-2 and Mcl-1, both of which are STAT3 target genes (Fofaria 
and Srivastava, 2014).  
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In this study, I investigated if altering FER kinase levels led to changes in 5B1 cell 
susceptibility to anoikis and found that 5B1 cells were resistant to anoikis, irrespective of 
whether or not FER kinase levels were decreased. When cultured in suspension, I noted 
that 5B1 cells grew in clusters or spheroids, whose size increased during the 6-day culture 
period of these experiments.  This is consistent with the concept that the cells survived and 
proliferated when cultured in suspension. Cell-to-cell contacts established within the 
spheroids may have provided growth and survival signals that contributed to 5B1 cell 
resistance to anoikis. In agreement with this proposal, when suspended colorectal 
carcinoma cells were dissociated into single cells, an increase in the levels of cleaved 
caspase-3 and its substrate poly(ADP-ribose) polymerase-1 (PARP-1) occurred, indicative 
of apoptosis. In contrast, when suspended cells were allowed to remain in spheroids no 
cleaved caspase-3 or PARP-1 was detected (Kondo et al., 2011). In the same manner, the 
cellular interactions may have contributed to 5B1 cell survival, and therefore future 
experiments should consider determining anoikis in a single-cell suspension of 5B1 cells.  
4.4 FER is necessary for normal 5B1 cell migration on laminin 
332 
Melanoma cell interaction with ECM proteins present in the skin, such as collagen I and 
laminin 332, are important for migration and invasion. Normal melanocytes exhibit 
different migration phenotypes when cultured on collagen I or laminin 332. Specifically, 
mouse primary melanocytes show greater migration on laminin-332 compared to collagen 
I (Crawford et al., 2017). Similarly, I found that 5B1 melanoma cell migration was greater 
on laminin 332 compared to collagen I or in the absence of any exogenously added ECM 
substrate. This increase in migration on laminin 332 was also observed in A375 human 
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melanoma cells (Tsuji et al., 2002), and was abrogated upon inhibition of integrin α3β1. 
Therefore, interactions between laminin 332 and α3β1 likely mediate these migration 
responses. Focal adhesion complexes are formed when laminin 332 binds to integrin α3β1, 
leading to association with actin microfilaments and cell migration (Marinkovich, 2007). 
The increase in 5B1 cell migration on laminin 332 may follow similar mechanisms.  
I have demonstrated that FER-deficient 5B1 cells seeded on laminin-332 show deficits in 
migration capability. In the same manner, FER is an important player for migration in other 
cells types through mechanisms that involve modulating cell adhesion to the surrounding 
ECM (Rosato et al., 1998). For example, the cell surface receptor α-dystroglycan (α-DG) 
and its interacting glycan ligands are important for cellular interaction with ECM proteins 
such as laminin. In human prostate and breast carcinoma cells, the downregulation of FER 
results in increased expression of laminin-binding glycans, due to an increase in the 
transcription of glycosyltransferases, which are necessary for their synthesis. Moreover, 
these cells also exhibit a decrease in cell migration (Yoneyama et al., 2012). Thus, by 
decreasing the expression of genes encoding glycans which bind to laminins, FER 
contributes to cell migration. In addition, upregulation of integrins α6- and β1 has been 
reported in FER knockdown breast carcinoma cells, inducing focal adhesion formation and 
inhibiting cell migration (Ivanova et al., 2013). Together, these studies suggest that FER 
promotes breast carcinoma cell migration by reducing attachment to the ECM through 
mechanisms that involve downregulation of adhesion molecules. Whether similar 
mechanisms are implicated in the positive modulation of 5B1 melanoma cell migration 
remains to be investigated.  
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4.5 The study of 5B1 melanoma tumour formation using the in 
vivo chicken chorioallantoic membrane model  
The CAM has been used as an excellent model for experiments pertaining to angiogenesis 
and metastasis. This in vivo model offers many advantages for the study of tumourigenesis, 
tumour invasion and metastasis. First, the highly vascularized and easily accessible CAM 
allows for easy grafting of tumour cells and provides cells with continued nourishment for 
survival and growth (Kain et al., 2014). Second, the immune system of the chicken embryo 
is immature until E18 (Friend et al., 1990). Implantation of tumour cells in this model takes 
place around E11, minimizing the loss of grafted human tumour cells due to immune 
defence responses.  Using this system, my study demonstrated the ability of the CAM to 
support the growth of 5B1 human melanoma xenografts. 
Although mouse models are frequently used in melanoma research (Sharma et al., 2015), 
the CAM model has recently gained momentum due to the short duration required for 
completion of the assays, easy accessibility and visibility. A recent study demonstrated that 
both the mouse and the CAM in vivo models can be used to effectively study human A375 
melanoma tumour growth and metastasis (Avram et al., 2017). The increased accessibility 
and vascularization of the CAM allows research on angiogenesis, whereas the longer 
periods of tumour growth achievable using mouse xenograft models allow for a detailed 
analysis of later stages of melanoma progression (Avram et al., 2017). The majority of 
CAM studies reported on melanoma progression have used mouse melanoma cell lines. 
For example, altered expression of connexin 43 and pannexin 1 in BL6 mouse melanoma 
cells grafted onto ex ovo CAMs have been used to determine the effect of these proteins on 
BL6 growth and its metastatic properties (Penuela et al., 2012; Ableser et al., 2014). In 
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addition, metastasis of mouse melanoma cells from the primary tumour to organs within 
the chicken embryo was investigated in these studies  (Penuela et al., 2012). In a similar 
manner, I attempted to study 5B1 cell metastasis from the primary tumour grafted onto the 
CAM to the chick embryo organs, such as liver and lungs, using PCR amplification of 
human Alu sequences. However, this approach was not successful, as non-specific 
amplicons were consistently obtained. It is also possible that 5B1 cells do not form 
substantial metastases within the short, 7-day period in which the CAM experiments must 
be completed before loss of host viability occurs.  
4.6 FER kinase and 5B1 melanoma cell invasion into the 
CAM 
Analysis of 5B1 cell invasion into the CAM was performed only on tumours in which GFP 
immunoreactivity was detected and there was no evidence of chromatin condensation, 
consistent with the concept that these specimens contained tumour cells which would have 
been viable at the time of tissue harvest. Of the total number of tumours assessed, I found 
that about half of the Control and FER 9 tumours failed to show GFP immunoreactivity 
and showed condensed chromatin, and I therefore termed them “necrotic” although 
multiple forms of cell death besides necrosis could have taken place, but were not assessed 
in these experiments. In contrast, very few “necrotic” FER 9 and Control tumours formed 
by cells that had been treated with dox for 5 days prior to grafting were observed. This 
suggests the possibility of a protective dox effect, however, the cells were grafted onto the 
CAM in the absence of dox. Therefore, the effects from culturing 5B1 cells in medium 
containing dox may have been maintained through multiple cell divisions in the CAM 
experiments. In our laboratory, analyses of 5B1 cell lysates cultured in the presence or 
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absence of dox have indicated changes in the abundance of some proteins due to dox 
treatment (I. Ivanova, L. Dagnino, unpublished observations). Therefore, this reinforces 
the necessity of proper controls, such as the Control plus dox condition in my study, for 
the effective interpretation and characterization of specific effects associated with FER 
silencing.  
Histological analysis demonstrated the capacity of 5B1 cells to invade through the 
chorionic epithelium into the CAM mesoderm. Similarly, analysis of tissue sections of 
murine B16-F10 melanoma xenografts demonstrated invasive behaviour in this system 
(Ribatti et al., 2013). In addition, in ovo CAM experiments using metastatic human uveal 
melanoma cells showed tumour formation and invasion into the CAM (Kalirai et al., 2015). 
However, studies on the invasive behaviour of human melanoma cells using the CAM 
model are limited, and therefore my studies now further demonstrate the broad applicability 
of this approach. My studies also showed that FER-deficient 5B1 tumours may have 
increased capacity to invade the CAM, suggesting that FER may function to attenuate the 
invasive ability of 5B1 cells, although additional experiments are needed to rigorously 
quantify the invasive ability of these cells. If this, indeed, is the case, it would contrast with 
in vitro studies with lung and breast carcinoma cells cultured onto Matrigel which exhibited 
invasive behaviour only in the presence of normal FER levels (Ahn et al., 2013; Ivanova 
et al., 2013). FER may modulate invasive potential differently when cells are cultured in 
vitro vs in vivo. Alternatively, at least some aspects of FER function may be cell-type 
specific. One key difference between the environment in culture and that surrounding the 
CAM is the presence of growth factors, chemoattractants and nutrient gradients. Contrary 
to in vitro conditions, the CAM, rich in growth factors and nutrients, may strongly attract 
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melanoma cells grafted on its surface. Significantly, FER-deficient neutrophils 
demonstrated increased motility towards the chemoattractant, WKYMVm, in comparison 
to FER-expressing neutrophils (Khajah et al., 2013). Similarly, in 5B1 cells, FER 
deficiency may result in the activation of alternative pathways that stimulate the movement 
of melanoma cells into the CAM.  
Another potential explanation for the apparent increase in FER-deficient 5B1 cell invasion 
can be attributed to the difference in proliferation that I observed between the FER-
expressing and FER-deficient 5B1 cells. I have shown that a decreased number of FER-
deficient cells were in the S-phase of the cell cycle, suggesting that these cells have a 
decreased proliferative capacity. Studies have focused on the interplay between the 
proliferative and invasive phenotypes of tumour cells (Gao et al., 2005; Tzamali et al., 
2014). Hepatocyte growth factor/scatter factor (HGF/SF), which activates the Met receptor 
tyrosine kinase, induces both proliferative and invasive responses from DBTRG-05MG 
(DB-P) human glioblastoma cells. The DB-P cells are highly invasive and proliferate less 
compared to a selected population of DB-P cells, named DB-A2, which are highly 
proliferative. In vitro invasion assays using Matrigel have shown that the DB-A2 cells are 
less invasive, suggesting that selecting for a highly proliferative phenotype in the DB-P 
cells resulted in decreased invasive potential. Notably, the more invasive DB-P cells 
expressed higher levels of RAS and HGF/SF induced increased phosphorylation of ERK 
(downstream effector in the RAS/MAPK pathway) and Akt (downstream effector of the 
PI3K pathway), suggesting that the Ras/MAPK and PI3K pathways are associated with the 
invasive phenotype (Gao et al., 2005). Perhaps the downregulation of FER in 5B1 cells, 
which resulted in a decrease in their proliferative potential, favoured the activation of 
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pathways associated with increased invasion, such as MAPK or PI3K, thereby promoting 
FER-deficient 5B1 cell invasion into the CAM. These possibilities will be important areas 
for future research.  
An important step in tumour cell invasion is the degradation of the extracellular matrix. 
The matrix metalloproteinases (MMPs) are enzymes that are primarily responsible for the 
degradation of various ECM components and are grouped as being either soluble or 
membrane-bound (membrane-type MMP, MT-MMP) MMPs.  Their activity is regulated 
in part by tissue inhibitor of matrix metalloproteinases (TIMPs), which bind to MMPs and 
inhibit their activity (Hofmann et al., 1999). The balance between levels of activated MMPs 
and TIMPs plays a key role in melanoma invasion (Hofmann et al., 2000). In vitro and 
mouse xenograft experiments show increased expression of active MMP2 in highly 
invasive melanoma cell lines (Hofmann et al., 1999). Additionally, overexpression of 
MT1-MMP stimulated Bowes melanoma invasion in Matrigel (Iida et al., 2004) and 
expression of MT3-MMP facilitated Bowes melanoma cell invasion into fibrin but not 
collagen I (Tatti et al., 2011). Therefore, the expression of MMPs varies depending on the 
surrounding matrix and between the numerous melanoma cell lines (Hofmann et al., 2000). 
FER deficiency in the 5B1 melanoma cells, may result in the upregulation of certain MMPs 
that promote the invasion of the cells into the CAM. Consequently, the relationship 
between FER and MMP and/or TIMP expression requires further investigation.   
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4.7 FER kinase effects on endothelial cell localization to 5B1 
tumours 
In addition to investigating invasion into the CAM, I examined the presence or absence of 
chick endothelial cells within the grafted tumour, indicative of endothelial cell migration 
from the CAM, which could be evidence of blood vessel formation within the tumour. The 
endothelial cells were easily detected following injection of lens culinaris agglutinin 
(LCA) into the blood vessels of E18 CAMs prior to harvesting. LCA has been shown to 
efficiently allow detection of the endothelial lining of arteries, veins and capillaries (Jilani 
et al., 2003). As a result, LCA has been used in studies pertaining to cancer cell 
intravasation, extravasation and metastasis (Kim et al., 2016; Deryugina and Quigley, 
2009). Significantly, to my knowledge, my study is one of only a handful to histologically 
examine tumours for the presence of LCA labelled endothelial cells, although this approach 
does not allow quantitative analyses. I detected endothelial cells within both FER-
expressing and FER-deficient tumours, suggesting that FER is not necessary for 
endothelial cell recruitment to the tumour.  This observation is in agreement with a recent 
study that reported no differences in tissue microvessel density in the stromal cells located 
within FER-expressing and FER-deficient renal cell carcinoma tumours, suggesting a 
minimal, if any, role of FER in angiogenesis in this type of tumour (Mitsunari et al., 2017). 
The mechanisms involved in recruitment of endothelial cells to the 5B1 melanoma 
tumours, and whether these endothelial cells mark functional vasculature will be important 
areas for future research.  
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4.8 Future directions  
I have demonstrated that FER kinase promotes 5B1 melanoma cell proliferation and 
migration, however the downstream effectors responsible for the observed phenotypes 
remain to be investigated. In addition, I showed using the CAM model that FER is not 
essential for endothelial cell recruitment to the tumour, however FER-deficient tumours 
exhibit increased invasion into the CAM. The role of FER in the subsequent metastatic 
cascade is yet to be elucidated. For example, extravasation of 5B1 cells (with and without 
FER) from CAM blood vessels could be studied by examining the transit of GFP-labelled 
FER expressing and FER-deficient melanoma cells through lectin-labelled vessels, using 
time-lapse video-microscopy (Kim et al., 2016).  
4.9 Limitations to the study  
This study used an inducible knockdown model to reduce FER kinase levels in the 5B1 
cells. An inducible system was used over a constitutive system as it allows to control the 
onset of shRNA expression. This is beneficial to clearly compare normal cell phenotypes 
to phenotypes observed at the onset of shRNA expression. Previous studies have shown 
that FER promotes cancer cell proliferation and survival therefore, constitutive reduction 
of FER levels in melanoma cells may not be favourable for cell growth. However, the 
introduction of inducible agents to cells presents as a limitation as it could affect cell 
behaviour, therefore it is important to have the appropriate controls to decipher the 
phenotypes presented only due to decreased protein levels.  
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I have shown that upon dox treatment there is a 65-90% decrease in FER levels, suggesting 
that a small amount of FER protein remains in the cells. The phenotypes observed in this 
study may therefore be contingent on the cells having some residual FER activity. It will 
be important to examine the effects of complete FER knockdown on 5B1 cell behaviour 
through gene knockout methods such as Crisper/Cas 9.  
In this study, 5B1 cell invasion into CAM mesoderm was measured by determining the 
number of sections that show GFP-expressing 5B1 cells within collagen III-positive CAM. 
This assay is limited in its ability to determine quantifiable differences in invasion between 
FER-expressing and FER-deficient cell groups, such as differences in the number of 
invasive cells or the depth of 5B1 cell invasion into CAM mesoderm. In vitro invasion 
assays such as the Boyden chamber or the vertical gel invasion assay may help address 
these questions. To better model cell invasion within a tumour microenvironment, 
Hernandez and others have presented an in vivo invasion assay where microneedles filled 
with ECM extracts like Matrigel are introduced into a primary tumour formed in a 
mouse/rat. Invasive cells from the tumour can enter the needle over the course of a few 
hours and thereafter analyzed for the number or type of cells (Hernandez et al., 2009).  
Additionally, I observed invasion into the CAM in tumour sections obtained at the end of 
the experimental timeline, one week after cells were grafted. Perhaps invasive phenotypes 
are different shortly after tumour formation, with one cell group acquiring a delayed ability 
to invade. It will be interesting to collect tumour samples at various time points in the 7-
day period to observe for any timely differences in invasion.  
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4.10 Concluding remarks   
Currently, treatment options for melanoma range from standard chemotherapy to targeted 
therapies and immunotherapy (Michielin and Hoeller, 2015). However, the response of 
patients with metastatic melanoma to chemotherapy and other treatment options is 
frequently limited due to the emergence of resistance (Nikolaou et al., 2012). Therefore, 
there is a pressing need to target additional pathways for therapy.  
Over 50% of melanomas have a B-RAF mutation (Sosman et al., 2012), including the 5B1 
melanoma cells. Therefore, these cells are an excellent model to characterize additional 
proteins that may promote growth and resistance to therapy in melanoma cells with B-RAF 
driver mutations. In this study I have shown that 5B1 cell proliferation and migration can 
be attenuated with the downregulation of FER. Additionally, our laboratory has shown that 
FER-deficient 5B1 cells are more susceptible to cisplatin cytotoxicity compared to FER-
expressing cells (X. Zheng, I. Ivanova, L. Dagnino, unpublished observations). This 
suggests a potential in targeting FER for combinatorial therapy with current treatments, 
such as cisplatin. Additionally, mutations in numerous other proteins, such as N-RAS, 
RAC1 and NF1, account for the heterogeneity of melanoma tumours. Therefore, it will be 
important to investigate FER function in different subsets of melanomas and determine its 
contribution to their malignant phenotypes.  
I have also shown that FER-deficient 5B1 cells are not susceptible to apoptosis when 
cultured in suspension and that they form tumours on and invade into the CAM. This 
suggests that FER may not be essential for melanoma tumour growth. However, a 
hypothesis to be tested is that FER may cooperate with oncogenic drivers to potentiate 
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malignant properties. The importance of crosstalk signalling events in the acquisition of 
carcinoma resistance to targeted drug therapies has recently become an area of intense 
study. In melanoma cells with BRAFV600E mutations, the administration of the B-RAF 
inhibitor, vermurafenib, alters the RAS-signalling pathway. Typically, activation of B-
RAF leads to the phosphorylation and activation of MEK, which in turn phosphorylates 
and activates ERK. Phosphorylated ERK then activates the transcription of various genes, 
including Sprouty (SPRY) (Lito et al., 2012). In humans, there are four SPRY forms, and 
they selectively interfere with signalling from RTKs, such as the EGFR and FGFR. SPRY 
interferes with EGFR signalling through various mechanisms, including inhibition of 
EGFR endocytosis and, consequently, signalling, as well as binding to the adaptor protein, 
Grb2, and thus preventing the formation of the Grb2 - SOS1 (RAS-specific guanine 
nucleotide exchange factor) complex, which is required for RAS activation (Hanafusa et 
al., 2002). In melanoma cells that express a constitutively active B-RAF mutant, inhibition 
by vemurafenib resulted in increased RAS, together with reduced SPRY levels (Lito et al., 
2012). Under these conditions, reduction in SPRY allowed partial restoration of EGFR 
endocytosis and signalling, resulting in the development of resistance to the vemurafenib 
treatment.  
FER is known to interact with EGFR in various carcinoma cells upon stimulation by either 
EGF or PDGF (Kim and Wong, 1995; Sangrar et al., 2015). In breast carcinoma cells in 
which the EGF pathway is amplified due to overexpression of HER2, FER deficiency 
resulted in increased EGFR internalization, and enhanced RAS signalling. However, this 
supranormal activation of EGFR pathways was toxic to the cells, resulting in cytostasis, as 
well as, increased sensitization to the EGFR inhibitor, lapatinib (Sangrar et al., 2015).  It 
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is possible that in cell systems with above normal levels of EGFR signalling, inhibition of 
FER might interfere with tumour growth and be used in conjunction with targeted 
therapies, such as lapatinib, to enhance the effect of the treatment and prevent the onset of 
treatment resistance. Clearly, additional research on FER and its relationship to various 
oncogenic drivers, and FER as a potential useful target for adjuvant therapy in subsets of 
melanomas, is needed.  
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Appendices  
Appendix A: Additional representative fluorescence micrographs depicting Control 
and FER 9 cell invasion into the CAM mesoderm 
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Figure A1. Control and FER 9 tumour cell invasion into the CAM mesoderm 
 Control and FER 9 cells (previously cultured in the presence or absence of dox) were 
grafted on E11 CAMs and then cultured for 7 days to promote tumour growth. On E18, 
tumours were excised and processed for immunohistochemistry analysis. Ten serial 
sections for each tumour were analysed for GFP immunoreactivity within collagen III-
positive areas, indicative of 5B1 cell invasion into the CAM mesoderm. Micrographs 
illustrate Control and FER 9 tumour cell invasion into the CAM. A-C are micrographs of 
3 different Control -dox tumours (tumours formed from Control cells cultured in the 
absence of dox). D-F are micrographs of 3 different Control +dox tumours (tumours 
formed from Control cells cultured in the presence of dox). G-I are micrographs of 3 
different FER 9 -dox tumours (tumours formed from FER 9 cells cultured in the absence 
of dox). J-L are micrographs of 3 different FER 9 +dox tumours (tumours formed from 
FER 9 cells cultured in the presence of dox). The white dotted line outlines the tumour-
CAM interface. White bar = 64 µm.   
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Appendix B: Additional representative fluorescence micrographs depicting 
endothelial cell localization to FER 9 tumours 
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Figure B1. Endothelial cell localization to FER 9 tumours. 
 FER 9 cells (previously cultured in the presence or absence of dox) were grafted on E11 
CAMs and then cultured for 7 days to promote tumour growth. On E18, rhodamine-labeled 
LCA was injected into a blood vessel of the CAM, tumours were excised and processed 
for immunohistochemistry analysis. Tumour specific regions, identified as areas not 
expressing collagen III, were analysed for rhodamine-LCA fluorescence, indicative of 
endothelial cells.  Micrographs illustrate endothelial cell localization to FER 9 tumours. A-
C are micrographs of 3 different FER 9 -dox tumours (tumours formed from FER 9 cells 
cultured in the absence of dox) and D-F are micrographs of 3 different FER 9 +dox tumours 
(tumours formed from FER 9 cells cultured in the presence of dox). C. Micrographs of 2 
different areas of the same FER 9 -dox tumour. F. Micrographs of 2 different areas of the 
same FER 9 +dox tumour. White bar = 64 µm.   
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